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 Sphingolipids are major components of the membrane bilayer and they 
play critical roles in regulating cancer development. The major bioactive 
sphingolipids, ceramide and sphingosine-1-phosphate (S1P), regulate very 
distinct cellular functions. Increased levels of ceramide have been shown to 
promote apoptosis, while increased levels of S1P promote cell proliferation 
and survival. A ‘sphingolipid rheostat’ has been proposed, whereby the 
relative levels of ceramide to S1P in living cells influence cell fate. The 
enzyme that is responsible for regulating this sphingolipid rheostat is 
sphingosine kinase (SphK), which catalyses the phosphorylation of 
sphingosine to S1P. SphK1 is the primary isoform that reduces pro-apoptotic 
ceramide levels by shifting the sphingolipid metabolism pathway towards the 
production of S1P, thereby tilting the rheostat towards cell survival. SphK1 
itself acts as an oncogene and is up-regulated in various forms of cancer. 
SphK1 potentiates cancer progression by sustaining important survival 
signaling pathways in cancer cells. Its expression correlates with poor 
prognosis in cancer patients. Therefore, SphK1 is a potential chemotherapy 
target, in view of the evidence supporting its oncogenic roles. 
 Colorectal cancer is the third most common cancer in the world and the 
fourth most common cause of death from cancer. It is an aggressive form of 
cancer for which we lack adequate therapy. Although SphK1 has gained 
increasing prominence as an oncogenic determinant in several cancers, its 
potential as a therapeutic target in colorectal cancer remains uncertain. In this 
project, we provided strong evidence for the emerging importance of SphK1 in 
colorectal cancer and the potential effectiveness of inhibiting SphK1 activity 
vii 
 
in chemotherapy. We demonstrated a definite correlation between high SphK1 
expression and advanced malignancy as well as poor survival in colorectal 
adenocarcinoma patients. Antagonism of the SphK1 pathway through a novel 
SphK1-specific inhibitor, Compound 5c, inhibits cell cycle progression, 
resulting in the apoptosis of colon cancer cells. SphK1 inhibition sensitizes 
cancer cells to 5-fluorouracil treatment, suggesting that SphK1 inhibitors 
should be explored for their potency as adjunct agents in current 
chemotherapeutic regimes. We further elucidated a novel SphK1-S1P-PKCδ-
Akt signaling pathway, revealing an alternative mechanism by which SphK1 
promotes the survival of colorectal cancer cells through its interactions with 
PKCδ and Akt signaling. Therapeutic strategies that employ the use of SphK1 
inhibitors are likely to disrupt these pro-survival mechanisms and drive the 
colorectal cancer cells towards death. Taken together, SphK1 is an important 
prognostic and oncogenic determinant in colorectal cancer. Drugs that target 
SphK1 if developed with acceptable toxicity may present a new therapeutic 
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1.1 Colorectal Cancer 
Colorectal cancer is the third most common cancer in the world and the 
fourth most common cause of death from cancer (Ferlay et al, 2010). 
Increased risk of colorectal cancer can be attributed to a high fat diet, family 
history of colorectal cancer and chronic ulcerative colitis. Colorectal cancer 
develops primarily from colorectal polyps and can be aggravated by 
inflammation of the inner lining of the colorectal (ulcerative colitis). 
Metastasis of colorectal cancer cells results in a drastic drop in the survival 
prognosis of patients, where a complete cure of the cancer is unlikely. 
Therefore, immediate treatment of primary colorectal tumors is crucial. 
Treatment of colorectal cancer commonly involves the resection of the 
primary tumor in the colorectal/rectum, followed by chemotherapy to prevent 
tumor recurrence and promote survival.  
 
1.1.1 Treatment strategies for colorectal cancer 
5-Fluorouracil (5-FU) is the first line treatment for advanced colorectal 
cancer. The 5-FU-based chemotherapy improves the survival chances of 
patients with resected stage III colorectal cancer (1995). Nonetheless, the 
response rates of 5-FU-based chemotherapy as a first-line treatment for 
advanced colorectal cancer are only 10-15% (Johnston & Kaye, 2001).  
Therefore, the current chemotherapy regimes that are used to treat 
colorectal cancer include a cocktail of 5-fluorouracil (5-FU), oxaliplatin, 
leucovorin and irinotecan that works together to inhibit DNA synthesis in 





cancer cells. 5-FU is a pyrimidine analog that is a non-competitive inhibitor of 
thymidylate synthase (Longley et al, 2003). 5-FU blocks the synthesis of 
thymidine - a key nucleotide for DNA synthesis. 5-FU is usually administered 
with leucovorin, an adjuvant drug, which enhances the inhibitory effects of 5-
FU on thymidylate synthase. Other cocktails include FOLFOX and FOLFIRI. 
FOLFOX is a cocktail of 5-FU, leucovorin and oxaliplatin (Giacchetti et al, 
2000). Oxaliplatin is a platinum-based alkylating agent that inhibits DNA 
synthesis. FOLFIRI is a cocktail of 5-FU, leucovorin and irinotecan (Douillard 
et al, 2000). Irinotecan is a topoisomerase 1 inhibitor that prevents DNA from 
unwinding, thereby inhibiting DNA synthesis. 
However, these drugs have undesirable side effects because they act on 
both cancer and normal cells. Severe side effects of 5-FU include 
myelosuppression, mucositis, dermatitis and cardiac toxicity (Saif et al, 2009). 
Severe side effects of oxaliplatin include neuropathy, neutropenia and 
ototoxicity (Grothey, 2003). Severe side effects of irinotecan include diarrhea 
and immunosuppression (Wasserman et al, 2001). Therefore, it is important to 
develop new drugs with higher potency and fewer side effects. More effective 
cocktails should be introduced to further lower the effective therapeutic doses 
of drugs such as 5-FU. 
Other than the current chemotherapeutic drugs, other strategies have 
also been explored in the treatment of colorectal cancer. These strategies are 
known as ‘targeted’ therapies (Mocellin et al, 2005). These ‘targeted’ 
therapies work on the basis that molecular mechanisms are dysregulated in 
cancer cells. Thus, by ‘attacking’ these dysfunctional mechanisms, one can 
target the cancer cells without affecting the normal cells. These therapies 





include interfering with cancer-related signaling pathways at the protein level; 
employing gene therapy to correct gene imbalances underlying tumor survival 
and aggressiveness; or utilizing the immune system of patients to recognize 
and kill cancer cells (immunotherapy) (Mocellin et al, 2005). 
A possible new area of research for colorectal cancer should be 
invested on the ‘double hit’ strategy (Mocellin et al, 2005), which refers to the 
potential combination of chemotherapeutic drugs with the ‘targeted’ therapies. 
This strategy is likely to be highly successful in the complete elimination of 
colorectal cancer cells. 
 
1.2 Sphingolipids 
 Sphingolipids are major components of the membrane bilayer and they 
play critical roles in regulating cancer development (Fyrst & Saba, 2010; 
Hannun & Obeid, 2008; Ogretmen & Hannun, 2004; Pyne & Pyne, 2010; 
Saddoughi et al, 2008). In the sphingolipid metabolism pathway, the precursor 
sphingomyelin is hydrolyzed by sphingomyelinase to ceramide. Ceramide is 
also produced de novo from the precusors palmitoyl coA and serine. Ceramide 
produced can be converted back to sphingomyelin by sphingomyelin synthase 
or be further converted to sphingosine by ceramidase. Sphingosine is 
phosphorylated by sphingosine kinase (SphK) to sphingosine-1-phosphate 
(S1P), which can be irreversibly degraded by S1P lyase to palmitaldehyde and 
ethanolamine phosphate. In the presence of S1P phosphatases found in the 
endoplasmic reticulum (ER), S1P can also be converted back sphingosine 
through the salvage pathway (Figure A). Lipids are regarded as bioactive 
when changes in their levels results in important functional consequences. The 





major bioactive sphingolipids, ceramide & sphingosine-1-phosphate (S1P), 
regulate very distinct cellular functions (Cuvillier et al, 1996). 
 
 
Figure A. The bioactive sphingolipids synthesis pathways 
In the sphingolipid metabolism pathway, the precursor sphingomyelin is 
hydrolyzed by sphingomyelinase to ceramide. Ceramide is also produced de 
novo from the precusors palmitate and serine. Ceramide produced can be 
converted back to sphingomyelin or be further converted by ceramidase to 
sphingosine. Sphingosine is phosphorylated by sphingosine kinase to 
sphingosine-1-phosphate, which can be irreversibly degraded by S1P lyase to 
palmitaldehyde and ethanolamine phosphate. In the presence of S1P 
phosphatases, S1P can also be converted back sphingosine via the salvage 
pathway. CDase, ceramidase; CerS, ceramide synthase; CK, ceramide kinase; 
GCase, glucosyl ceramidase; GCS, glucosylceramide synthase; SphK1, 
sphingosine kinase 1; SMase, sphingomyelinase; SMS, sphingomyelin 









1.2.1 The Sphingolipid Rheostat  
 A ‘sphingolipid rheostat’ has been proposed (Figure B), whereby the 
relative levels of ceramide to S1P in living cells influence cell fate. Cuvillier et 
al first showed that ceramide production induces apoptotic cell death 
(Cuvillier et al, 1996). Importantly, they demonstrated that the production of 
S1P is able to suppress this response and rescue cells from the ceramide-
induced apoptosis. This sphingolipid rheostat is most evident in anti-cancer 
therapy resistant/sensitive cell lines. For example, daunorubicin-resistant 
leukemia cell lines exhibit higher S1P levels and daunorubicin-sensitive cell 
lines exhibit higher ceramide levels (Sobue et al, 2008). Therefore, the balance 
between ceramide/S1P levels is important in tumor progression and careful 







































Figure B. The sphingolipid rheostat 
The sphingolipid rheostat refers to the relative levels of ceramide to S1P in 
living cells that determines cell fate. Increased ceramide production induces 
apoptotic cell death, while increased S1P production suppresses this response 
and rescues cells from ceramide-induced apoptosis. CDase, ceramidase; CerS, 
ceramide synthase;  SphK1, sphingosine kinase 1; SPPase, sphingosine-1-





























Figure C. The distinct roles of the bioactive sphingolipids 
Upon the exposure to a diverse range of stimulants, the bioactive sphingolipids 
ceramide, sphingosine and sphingosine-1-phosphate respond and exert distinct 
cellular effects.  The numbers in bracket indicate the relative levels of the 
respective sphingolipids. CAPP, ceramide-activated Ser-Thr phosphatase; 
IGF, insulin growth factor; IL-1, interleukin-1; oxLDL, oxidized low-density 
lipoprotein; PDGF, platelets-derived growth factor; PKC, protein kinase C; 
PKH, PKB homologue; TNFα, tumor necrosis factor-α; VEGF, vascular 
endothelial growth factor; YPK, yeast protein kinase. (Reprinted from Nature 
Reviews Molecular Cell Biology, Vol 9, Hannun YA and Obeid LM, An 
overview of the roles of sphingolipids in biology, Page 139-50., Copyright 












Ceramide accumulates in response to stress stimuli such as ionizing 
radiation, chemotherapy, serum withdrawal, cytokine treatment and oxidative 
stress (Jaffrézou et al, 2001; Kolesnick & Hannun, 1999; Levade & Jaffrézou, 
1999; Lozano et al, 2001; Mathias et al, 1998; Morita et al, 2000; Paris et al, 
2001). The subcellular production of ceramide influences its downstream 
effector functions. Ceramide can accumulate in the plasma membrane, 
mitochondria, lysosomes, ER and nucleus (Saddoughi et al, 2008). For 
example, ceramide accumulates at the plasma membrane from the 
acidic/neutral sphingomyelinase-induced hydrolysis of sphingomyelin, and in 
the ER via the de novo synthesis (Figure A). These accumulations of ceramide 
induce cell growth arrest and pro-apoptotic signals that activate caspases, 
which in turn induces apoptosis (Obeid et al, 1993). Therefore, in response to 
stress stimuli, ceramide drives cells towards death. 
Oocyte apoptosis is a side effect experienced in female patients 
undergoing anti-cancer therapy, which leads to a loss of ovary reproductive 
potential. This is attributed to an accumulation of ceramide (Morita et al, 
2000). Disruption of the sphingomyelinase gene or S1P therapy help to 
overcome this ceramide-induced oocyte apoptosis. 
Accumulation of ceramide contributes to radiation and chemotherapy-
induced apoptosis (Chmura et al, 1997b; Chmura et al, 2000; Jaffrézou et al, 
2001; Kolesnick & Hannun, 1999; Lozano et al, 2001; Mathias et al, 1998; 
Paris et al, 2001). For example, ceramide promotes daunorubicin and 
vincristine-induced apoptosis in leukemia cells (Mathias et al, 1998). Stress 
stimuli such as ionizing radiation activate neutral sphingomyelinase in the 





nucleus, thereby increasing ceramide production and decreasing 
sphingomyelin levels (Chmura et al, 1997b; Chmura et al, 2000; Jaffrézou et 
al, 2001). Increase in ceramide levels induce pro-apoptotic effects such as 
increased poly ADP ribose polymerase (PARP) cleavage (Jaffrézou et al, 
2001), intracellular reactive oxygen species (ROS), mitochondrial 
permeability and cytochrome c release (Chmura et al, 2000). Therefore, cancer 
cells with defective ceramide production are more resistant to radiation 
therapy (Jaffrézou et al, 2001; Mathias et al, 1998; Paris et al, 2001). This is 
further strengthened by the findings of Paris et al, who showed that the acid 
sphingomyelinase-mediated ceramide generation induces microvascular 
endothelial apoptosis (Paris et al, 2001). This contributes to gastrointestinal 
tract damage by chemotherapy and radiation. Acid sphingomyelinase knock-
out mouse embryonic fibroblasts are thus resistant to apoptosis induced by 
radiation, cytokine and serum withdrawal (Lozano et al, 2001). Increased 
expression of glucosylceramide synthase also contributes to death resistance 
of cancer cells, due to increased conversion of ceramide to glucosylceramide 
(Liu et al, 2001). Nonetheless, the addition of exogenous ceramide or 
inhibition of SphK activity overcomes the resistance to death in these cancer 
cells (Chmura et al, 1997b; Jaffrézou et al, 2001; Lozano et al, 2001), 
demonstrating the importance of ceramide in regulating cell death and 
enhancing anti-cancer therapies. 
 
1.2.3 Sphingosine-1-phosphate 
S1P is maintained at very low levels in resting cells. But it can be 
rapidly increased by growth factors, cytokines and other signaling proteins 





(Spiegel et al, 1998). Production of S1P regulates important survival signaling 
proteins such as the mitogen-activated protein kinase (MAPK), c-Jun N-
terminal kinase (JNK) and phospholipase D (PLD). This suggests a role for 
S1P in cell survival. S1P also regulates important second messengers in cells 
such as calcium and cyclic adenosine monophosphate (cAMP) (Spiegel et al, 
1998). Therefore, S1P has a diverse range of biological functions including 
mammalian brain and cardiac development; maturation of systemic circulatory 
system and lymphatics; trafficking and effector functions of lymphocytes and 
other hematopoietic cells; protection against tissue injury. Importantly, S1P is 
an oncogenic lipid and increased levels of S1P promote cancer cell 
proliferation and survival. 
S1P produced upon SphK activation can either be retained 
intracellularly, or be exported out of cells to function extracellularly. 
Extracellular S1P acts as a first signaling messenger by binding to specific G-
protein coupled receptors (GPCRs) labeled as S1P1-5 and re-entering cells in 
an autocrine or paracrine manner (Spiegel & Milstien, 2003). Intracellular S1P 
that remains in the cytosol acts as a second signaling messenger upon the 
addition of stimulants such as serum and platelets-derived growth factor 
(PDGF) (Olivera et al, 1999; Olivera & Spiegel, 1993). Both intracellular and 
extracellular S1P have distinct functions. Extracellular functions include 
growth, metastasis, angiogenesis and vascular maturation, lymphocyte 
trafficking, immunity and allergic responses (Hait et al, 2006; Hla, 2005; 
Milstien & Spiegel, 2006; Rosen & Goetzl, 2005; Taha et al, 2006). 
Intracellular functions include calcium release, proliferation and protection 
from apoptosis (Hobson et al, 2001; Kohno et al, 2006; Olivera et al, 2003).  





Interestingly, the mitogenic properties of S1P have been shown to be 
independent from its receptors (Van Brocklyn et al, 1998). Binding of S1P to 
S1P1 inhibits cAMP accumulation. Inhibition of cAMP affects the 
polymerization / depolymerization of actin filaments, thus influencing cell 
motility. However, this receptor-bound S1P did not induce cell proliferation & 
survival. It also did not protect cells from apoptosis. On the other hand, the 
microinjection of S1P into cells induces DNA synthesis and promotes cell 
survival. The role of extracellular S1P in cell motility is further backed up by 
studies done by Rosenfeldt et al, who showed that S1P receptors signal 
downstream to Rac and p38 to regulate cytoskeletal rearrangements and focal 
adhesion turnover, mediating cell motility (Rosenfeldt et al, 2001).  
SphK overexpression models are good tools to study the intracellular 
roles of S1P. Overexpression of SphK in NIH3T3 fibroblasts increases 
intracellular S1P, but not extracellular S1P (Olivera et al, 1999). This 
overexpression of SphK promotes DNA synthesis and cell growth, even under 
low serum conditions. It also protected cells from the ceramide-induced 
apoptosis during serum withdrawal by inhibiting caspase activation. In 
leukemia cells, addition of the tumor necrosis factor (TNF) induces ceramide 
production, which induces apoptosis (Cuvillier et al, 1996). However, 
activation of protein kinase C (PKC) suppresses these effects by activating 
SphK to produce S1P. The intracellular S1P produced suppresses the apoptotic 
effects of ceramide. Therefore, cancer cells can potentially exploit the 









1.3 Sphingosine kinase 
 The enzyme that is responsible for regulating the sphingolipid rheostat 
is sphingosine kinase (SphK), which catalyses the phosphorylation of 
sphingosine to S1P.  Therefore, the expression level and activity of SphK 
influence the survival status of cells. 
 There are two cloned isoforms of SphK in mammalian cells – SphK1 
and SphK2. SphK1 lies on chromosome 17q25.2 while SphK2 lies on 
chromosome 19q13.2. Although SphK1 and SphK2 are isoforms, they have 
very distinct cellular functions (Maceyka et al, 2005). Maceyka et al attributes 
this to their different subcellular localization. 
SphK1: SphK1 promotes cell survival by blocking the production of 
ceramide (pro-apoptotic) (Maceyka et al, 2005). SphK1 is predominantly 
cytosolic and only translocates to the plasma membrane when the cells are 
stimulated by growth factors. At the plasma membrane, SphK1 phosphorylates 
sphingosine to S1P, which negatively regulates ceramide synthase, the enzyme 
that converts sphingosine back to ceramide. This S1P produced is 
subsequently irreversibly degraded by S1P lyase, so that it cannot be re-
converted back to sphingosine and ceramide.  
SphK2: SphK2 promotes cell death by enhancing the production of 
ceramide (Maceyka et al, 2005). SphK2 is mainly localized to the plasma 
membranes and internal membranes such as the endoplasmic reticulum (ER) 
and nucleus. Lower levels are found in the cytosol. Upon serum starvation, 
SphK2 translocates from the cytosolic to the ER, where it phosphorylates 
sphingosine to S1P. SphK2 enhances the production of ceramide by ‘working 
alongside’ S1P phosphatase to convert the S1P produced back to sphingosine 





and ceramide via the salvage pathway. In the ER, SphK2 also aids in the de 
novo synthesis of ceramide by increasing the incorporation of palmitoyl coA 
to ceramide. These pro-apoptotic effects of SphK2 are independent of S1P 
receptors. Interestingly, artificial targeting of SphK1 to the ER switches it 
from pro-survival to pro-apoptotic, emphasizing that both SphK1 and SphK2 




 In resting cells, there is an intrinsic basal level of SphK1 activity and 
majority of the protein is present in the cytosol. However, upon stimulation by 
growth factors, SphK1 is phosphorylated at the serine residue 225 and is 
translocated to the plasma membrane where sphingosine is present (Pitson et 
al, 2005). SphK1 then phosphorylates sphingosine to S1P, thereby tilting the 
sphingosine rheostat towards promoting survival. Therefore, the translocation 
of SphK1 to the plasma membrane appears to be a crucial process for cancer 
cell survival and transformation.  
 SphK1 is the primary isoform that shifts the sphingolipid metabolism 
pathway towards the production of S1P, thereby reducing pro-apoptotic 
ceramide levels and tilting the rheostat towards cell survival (Maceyka et al, 
2005). SphK1 mRNA is up-regulated in various solid tumors (French et al, 
2003) and SphK1 acts as an oncogene (Xia et al, 2000). Fibroblasts 
overexpressed with SphK1 have increased foci formation; increased colonies 
formed in soft agar and increased tumorigenicity when injected into nude mice 
(Xia et al, 2000). SphK1 promotes cell growth, even under serum deprivation 





conditions (Xia et al, 2000). In addition, transformation of cells by the 
oncogene Ras requires the activation of SphK1 (Xia et al, 2000). Therefore, 
SphK1 is an oncogene important in promoting the survival of cancer cells.  
 SphK1 sustains important survival mechanisms in cancer cells such as 
the mitogen-activated protein kinase (MAPK) (Nava et al, 2002 ; Pitson et al, 
2005; Shu et al, 2002), the phosphoinositide-3-kinase/protein kinase B 
(PI3K/Akt) (Ader et al, 2008; Kapitonov et al, 2009; Le Scolan et al, 2005; 
Radeff-Huang et al, 2007), and PKC (Johnson et al, 2002) signaling pathways. 
SphK1 also interferes with the apoptotic pathway to promote survival. For 
example, SphK1 up-regulates anti-apoptotic Bcl2 and down-regulates pro-
apoptotic Bim (Limaye et al, 2005). It inhibits the release of cytochrome c and 
the second mitochondria-derived activator of caspases (SMAC) from the 
mitochondria, as well as the activation of caspase 3 (Bonhoure et al, 2008). 
SphK1 is in turn regulated by Bcl2 (Bektas et al, 2005). However, there are 
still no known genetic mutations of SphK1 found in cancer cells. Thus, studies 
have suggested that SphK1 contributes to tumor development via non-
oncogene addiction (Vadas et al, 2008). This means that the cancer cells are 
over-reliant on SphK1 that is over-expressed by mechanisms other than 
genetic mutations/amplifications. It is further hypothesized that the ability of 
cancer cells to survive is governed by a threshold level of SphK1 activity 
(Pyne & Pyne, 2010). Therefore, effective therapy depends on the ability to 
reduce SphK1 activity below threshold levels. Combination therapy of current 
chemotherapeutic drugs together with a potent SphK1 inhibitor might be more 
effective. 
 





1.3.2 SphK1 in various cancer models 
 SphK1 has been shown to be up-regulated in various cancer models, 
including brain, prostate, leukemia, breast, pancreatic, gastric and colorectal 
cancer.  
 SphK1 in brain cancer: In glioblastoma patients, SphK1 expression 
but not SphK2 correlates with poor survival prognosis (Van Brocklyn et al, 
2005). Blockade of SphK activity in vitro down-regulates glioblastoma cell 
proliferation by arresting cells in the G1 cell cycle phase. Apoptosis is also 
enhanced with this blockade. This does not involve the S1P receptors (Van 
Brocklyn et al, 2005). Similarly, in astrocytoma patients, SphK1 expression 
correlates with increasing clinical grade and poor survival prognosis (Li et al, 
2008).  SphK1 is also up-regulated in various astrocytoma cell lines (Li et al, 
2008). Therefore, SphK1 may be developed as a prognostic marker in brain 
cancer. 
 SphK1 in prostate cancer: Chemotherapeutic drugs such as docetaxel 
and camptothecin are used in the treatment of prostate cancer. These drugs 
inhibit SphK1 activity and tilt the sphingolipid rheostat to favor production of 
pro-apoptotic ceramide (Akao et al, 2006; Pchejetski et al, 2005). In drug-
resistant prostate cancer cells, SphK1 is often over-expressed. Inhibition of 
SphK1 in these cells helps to overcome drug resistance, resulting in smaller 
tumor volumes and reduced metastasis (Pchejetski et al, 2005). Activation of 
SphK1 is also a survival mechanism employed by prostate cancer cells during 
anti-cancer treatments such as androgen depletion. Androgen deprivation 
therapy is the standard treatment for patients with advanced prostate cancer 
(Dayon et al, 2009). However, androgen depletion activates SphK1, which 





helps the cells to survive the androgen-deprived conditions. In addition, 
SphK1 activation adapts cells towards the acquisition of a neuroendocrine 
(NE)-like cell phentoype, which allows prostate cancer cells to be androgen-
independent for survival (Dayon et al, 2009). The transformation of prostate 
cancer cells under the influence of SphK1 thus renders these cells resistant to 
androgen deprivation therapy. Therefore, SphK1 is proposed to act as a 
chemotherapy sensor, whereby the expression of SphK1 in prostate cancer 
cells determines how well the patient will respond to chemotherapy 
(Pchejetski et al, 2005).  
 SphK1 in leukemia: In leukemia, SphK1 is up-regulated (Sobue et al, 
2006) and confers growth advantage by increasing the colony formation 
potential and promoting resistance to apoptosis during serum deprivation (Le 
Scolan et al, 2005). This requires the phosphorylation and activation of 
downstream pro-survival proteins such as Akt and the extracellular signal-
regulated kinases (ERK1/2). Pro-survival SphK1 contributes to leukemic cell 
resistance to death by chemotherapy drugs such as imatinib (Baran et al, 2007; 
Bonhoure et al, 2008). Inhibition of SphK1 activity thus helps to overcome 
resistance to imatinib treatment and the combination of SphK1 inhibitors with 
imatinib potently drives the death of leukemia cells. This emphasizes the 
potential of SphK1 inhibitors as anti-cancer drugs. 
 SphK1 in breast cancer: In breast cancer, SphK1 is shown to be 
important for migration, proliferation and survival of cancer cells (Nava et al, 
2002; Sarkar et al, 2005). The hormone estrogen and EGF activate SphK1 
activity, which in turn activates downstream ERK1/2 to promote cell growth 
(Nava et al, 2002). Inhibition of SphK1 enhances the sensitivity of breast 





cancer cells to the chemotherapeutic drug doxorubicin (Nava et al, 2002). In 
estrogen-positive tumors, SphK1 expression correlates with poor survival 
prognosis of patients (Ruckhäberle et al, 2008). No correlation was found for 
SphK2 or S1P receptors. SphK1 expression is also higher in the estrogen-
negative tumors (Ruckhäberle et al, 2008). Such tumors grow independently 
of estrogen, and patients usually have poorer prognosis and require more 
aggressive treatments.  
 SphK1 in pancreatic cancer: In pancreatic cancer, SphK1 has also 
been shown to be up-regulated in human tumor tissues and the sphingolipid 
rheostat determines the survival of pancreatic cancer cells (Guillermet-Guibert 
et al, 2009). The rheostat has further been proposed to be a chemotherapy 
sensor for the sensitivity of pancreatic cancer cells to gemcitabine. 
Gemcitabine-resistant pancreatic cell lines have elevated levels of S1P and 
SphK1 activity. Therefore, blockade of SphK1 activity helps to overcome 
resistance to gemcitabine. 
 SphK1 in gastric cancer: Likewise in gastric cancer, the SphK1 
mRNA and protein is up-regulated in gastric cancer cell lines and primary 
gastric tumors (Li et al, 2009). SphK1 is over-expressed in human gastric 
cancer histology samples. Preliminary studies showed that SphK1 correlates 
with poor survival prognosis and advanced clinical staging. More studies are 
needed to further understand the roles of SphK1 in promoting the development 










 SphK2 has a broader substrate specificity than SphK1 because other 
than sphingosine, it also phosphorylates phytosphingosine and FTY720. In the 
last 10 years, the biological functions of SphK2 have been consistently 
debated. It is no longer absolute that SphK2 is pro-apoptotic, with functions 
opposing that of SphK1. Studies have demonstrated that SphK2 can be both 
pro-apoptotic (Igarashi et al, 2003; Liu et al, 2003; Maceyka et al, 2005; 
Okada et al, 2005) and pro-survival (Hait et al, 2007; Hait et al, 2005; Sankala 
et al, 2007; Schnitzer et al, 2009; Weigert et al, 2009), depending on the 
cellular context and disease model.  
 Pro-apoptotic roles of SphK2: In the model of prostate cancer (Liu et 
al, 2003), Liu H and group showed that SphK2 has a unique BH3 domain that 
allows it to interact with the pro-survival Bcl2 members as well as the pro-
apoptotic BclXL in the cytosol. In addition, this cytosolic SphK2 induces 
cytochrome c release and caspase 3 activation, thereby inducing apoptosis and 
suppressing proliferation. This pro-apoptotic effect of SphK2 is independent 
of S1P receptor activation (Liu et al, 2003).  
 There are 2 known forms of SphK2 (Igarashi et al, 2003; Okada et al, 
2005) – SphK2-Short (SphK2-S) and SphK2-Long (SphK2-L). SphK2-L 
differs from SphK2-S by the presence of an extended N terminal. SphK2-L 
has been found to be the major form of SphK2 in several cell lines and tissues, 
and it is only found in humans (Okada et al, 2005). Both SphK2-L and SphK2-
S can enter the nucleus to influence DNA synthesis. Igarashi N and group 
showed that there is a nuclear localization signal (NLS) fused to the N-
terminal of SphK2-S (Igarashi et al, 2003). The NLS is a unique feature not 





found on SphK1. This NLS allows SphK2-S to enter the nucleus, where it 
inhibits DNA synthesis and induce G1/S phase cell cycle arrest (Igarashi et al, 
2003). Upon serum deprivation, SphK2-L also enters the nucleus to inhibit 
DNA synthesis, block cell proliferation, and enhance apoptosis (Okada et al, 
2005). Thus, the nuclear activities of SphK2 contribute to its pro-apoptotic 
roles. 
 Other pro-apoptotic mechanisms of SphK2 include phosphorylating 
and activating FTY720 which is a S1P receptor antagonist. Binding of 
FTY720 desensitizes the S1P1 receptors, thereby down-regulating the 
extracellular signaling of S1P (Rosen & Goetzl, 2005). SphK2 is also able to 
localize to the endoplasmic reticulum (ER) where it increases ceramide levels 
and promote apoptosis (Maceyka et al, 2005).  
 Pro-survival roles of SphK2: On the other hand, many studies have 
demonstrated the tumor-promoting roles of SphK2, where it appears to be 
important for tumor proliferation, migration and resistance to chemotherapy. 
SphK2 promotes cell proliferation of tumors such as glioblastomas (Van 
Brocklyn et al, 2005). In breast cancer, SphK2 is activated by growth factors 
such as EGF and phorbol myristate acetate (PMA) (Hait et al, 2007 ; Hait et al, 
2005). In the absence of SphK2, breast tumor xenografts grow slower and 
tumor-associated macrophages (TAMs) are driven towards anti-tumor 
phenotypes (Weigert et al, 2009). Activation of SphK2 also induces cell 
migration in a cell-type specific fashion (Hait et al, 2007; Hait et al, 2005). 
Importantly, activated SphK2 promotes resistance to chemotherapy (Sankala 
et al, 2007). Cell cycle arrest induced by chemotherapy has been shown to 
contribute to chemotherapy resistance. Upon chemotherapeutic treatment, p21 





(a p53 target gene) induces cell cycle arrest to allow time for cells to repair 
and recover from DNA damage. Knockdown of SphK2 reduces p21 levels and 
shifts the machinery from cell arrest to cell death (Sankala et al, 2007). 
Reduction in SphK2 levels thus helps to overcome resistance of cancer cells to 
chemotherapy. In the model of lung cancer, Schnitzer SE et al further showed 
that SphK2 promotes chemoresistance under hypoxic conditions (Schnitzer et 
al, 2009).  
 Overall, studies have demonstrated both pro-survival and pro-apoptotic 
roles of SphK2. Unlike SphK1 that is predominantly pro-survival, the 
functional effects exerted by SphK2 are largely dependent on the disease 
model-of-interest, the cellular location of SphK2 and the molecular players 
surrounding it. Targeting SphK2 in cancer therapy is thus more challenging 
and unpredictable. 
 
1.4 Sphingolipids in Colorectal Cancer 
 In recent years, there is increasing evidence that sphingolipids such as 
ceramide, S1P and SphK are important players in colorectal cancer 
development. Most of the studies have focused on the role of ceramide in 
contributing to apoptosis of colorectal cancer cells. The roles of SphK1 and 
S1P, on the other hand, are relatively less studied in colorectal cancer. 
 
1.4.1 Ceramide in Colorectal Cancer 
 Ceramide is down-regulated in colorectal cancer as a signaling defect 
to promote cancer cell survival. Ceramide is pro-apoptotic in colorectal cancer 
because accumulation of ceramide via the inhibition of ceramidase down-





regulates colorectal cell viability (Selzner et al, 2001). This accumulation of 
ceramide levels induces cytochrome c release, caspase 3 activation and DNA 
fragmentation. Ceramide activates caspases by the activation of peroxisome 
proliferator-activated receptor γ (PPARγ) and downstream JNK pathway 
(Wang et al, 2006). Ceramide has also been shown to arrest cells in the G2/M 
phase and induce apoptosis (Ahn & Schroeder, 2002; Veldman et al, 1998). 
Treatment of nude mice with the ceramidase inhibitor B13 completely 
prevented the growth of colorectal tumor without inducing toxicity to normal 
tissues (Selzner et al, 2001). White-Gilbertson et al also demonstrated the 
importance of ceramide in driving the death of colorectal cancer cells (White-
Gilbertson et al, 2009). They showed that colorectal cancer cells that are 
resistant to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-
induced cell death have lower levels of ceramide synthase 6 (CerS6). This 
results in lower production of ceramide. The knock-down of CerS6 inhibits 
translocation of active caspase 3 into the nucleus, thereby preventing apoptosis 
of colorectal cancer cells. Therefore, the up-regulation of CerS6 to restore 
ceramide levels in these cells overcomes the death resistance and induces 
apoptosis. 
 A study by Dahm et al showed that the ceramide analogue LCL-30 can 
be targeted to the mitochondria of colorectal cancer cells and induces 
cytotoxicity by reducing adenosine triphosphate (ATP) levels (Dahm et al, 
2008). ATP is the energy source of cells. Without ATP, the pro-survival 
reactions cannot occur, thereby inducing cytotoxicity. The effects of this 
ceramide analogue did not involve the activation of caspases or cytochrome c 





release. This new finding is further validated in a mice model, whereby LCL-
30 inhibited subcutaneous tumor growth (Dahm et al, 2008). 
 An interesting study carried out by Berra et al showed that the 
supplementation of sphingomyelin to the diet of mice reduces the formation of 
aberrant colorectalic crypt foci and colorectal adenocarcinomas (Berra et al, 
2002). The hypothesis is that these exogenous sphingolipids can bypass the 
sphingolipid-signalling defect present in colorectal cancer cells, thereby 
allowing ceramide to be produced to induce the death of these cancer cells. 
 
1.4.2 SphK1/S1P in Colorectal Cancer 
 S1P is maintained at low levels in normal intestinal tissues (Oskouian 
& Saba, 2007) and it protects normal intestinal epithelial cells from apoptosis 
(Greenspon et al, 2009). The generation of S1P in the colon is largely 
dependent on SphK1, the predominant sphingosine kinase isoform in the colon 
(Oskouian & Saba, 2007). In transformed neoplastic tissues, S1P accumulates 
and contributes to polyp enlargement and tumor progression (Oskouian & 
Saba, 2007). This increase in S1P levels aids in colorectal tumor growth and 
metastasis, chemotherapeutic resistance and inflammation.  
 SphK1/S1P in the patho-development of colorectal cancer: SphK1 
is significantly up-regulated in human colorectal cancer samples, especially 
those with metastasis (Kawamori et al, 2009). S1P produced with the up-
regulation of SphK1 is further sustained with the down-regulation of S1P 
lyase (Oskouian & Saba, 2007). Azoxymethane is a common carcinogen used 
to induce colorectal tumor formation and cyclooxygenase-2 (COX2) is a well-
established pathogenic factor that promotes the development of colon tumors. 





The use of azoxymethane induces SphK1 expression and S1P production, 
which in turn regulates downstream COX2 activity and prostaglandin E2 
(PGE2) production (Kawamori et al, 2006). Therefore, SphK1 is a potential 
therapeutic target because it regulates COX2 in the patho-development of 
colorectal cancer (Ogretmen & Hannun, 2004).  
SphK1/S1P in colorectal tumor growth and metastasis: Knockout 
mice models further validated that SphK1 is important in the progression of 
colorectal tumor development, induced by azoxymethane (Kawamori et al, 
2009; Kohno et al, 2006). SphK1 knockout mice had significantly lesser 
aberrant crypt foci (ACF) formation, reduced cell proliferation and increased 
apoptosis, overall inhibiting tumor development (Kawamori et al, 2009). In 
addition, SphK1 knockout did not reduce the incidence of intestinal polyps, 
but significantly reduced the size of the polyps and rate of adenoma cell 
proliferation (Kohno et al, 2006). This pro-survival effect of SphK1 did not 
involve the S1P receptors, suggesting a role for intracellular S1P instead 
(Kohno et al, 2006). Interestingly, knockout of SphK1 in this study did not 
inhibit downstream proteins such ERK1/2, pp38, COX2 and β-catenin, 
suggesting that SphK1 may be regulating cell survival via other pro-survival 
proteins (Kohno et al, 2006). However, SphK1 induces the expression of the 
oncogene c-myc and the cyclin dependent kinase 4 (CDK4), which is the 
regulator of the cell cycle G1/S phase (Kohno et al, 2006). This suggests that 
SphK1 may be driving cell cycle progression to promote cell proliferation.  
SphK1/S1P in ulcerative colitis: SphK1 is involved in ulcerative colitis, 
which refers to the inflammation of the colon. In the model of dextran sulfate 
sodium (DSS) induced colitis (Snider et al, 2009), knockout SphK1 mice 





treated with DSS had reduced inflammatory responses and as a result, less 
severe colitis. These mice also could not up-regulate COX2 expression upon 
induction by the pro-inflammatory cytokine TNF. 
In conclusion, SphK1 and intracellular S1P are important in the 
development of colorectal cancer. Their levels in colon needs to be tightly 
regulated to prevent neoplastic transformation. 
 
1.5 Inhibition of SphK & S1P 
 As the bioactive sphingolipid S1P and its regulating enzyme SphK1 
gain more recognition in the field of cancer development, understanding their 
biological roles and mechanisms of action becomes crucial. The use of 
inhibitors that specifically block the activity of SphK1 and consequently the 
production of S1P helps in this understanding. They are also potential 
therapeutic agents to treat cancer. 
 
1.5.1 Conventional inhibitors of SphK 
 Conventional inhibitors used to study SphK activity include D,L-threo-
Dihydrosphingosine (DHS), N,N-dimethylsphingosine (DMS) and N,N,N-
trimethylsphingosine (TMS). They were developed as analogues of 
sphingosine, which is the natural substrate of SphK. However, DHS, DMS and 
TMS are not selective inhibitors of SphK and its respective isoforms (SphK1 
and SphK2). At high doses, they inhibit PKC activity as well.  
 DHS, also known as sphinganene, inhibits SphK activity in platelets 
where S1P is abundant (Buehrer & Bell, 1992). However, inhibition by DHS 
is not specific to SphK. DHS inhibits PKC as well. The L-threo enantiomer of 





DHS, known as Safingol, is a specific inhibitor of PKC and it potentiates 
apoptosis in gastric cancer cells (Schwartz et al, 1995). DHS is also not a good 
therapeutic agent because it causes hepatotoxicity in mice (Buehrer & Bell, 
1992).  
 Both DMS and TMS inhibit SphK1 via competitive inhibition. This 
means that they bind to the active site of SphK1 and prevent the substrate 
sphingosine from binding. On the other hand, DMS inhibits SphK2 via non-
competitive inhibition. DMS and TMS potently inhibit cancer cell 
proliferation in vitro and reduces tumor growth in vivo (Endo et al, 1991). 
DMS also induces apoptosis in a variety of cancer cell lines, including colon 
cancer (Sweeney et al, 1996). However, both DMS and TMS inhibit PKC 
activity as well (Endo et al, 1991; Khan et al, 1990; Park et al, 1994) and their 
anti-cancer effects may be attributed to the inhibition of PKC rather than SphK 
(Endo et al, 1991). Edsall et al have shown that low doses of DMS (e.g.10μm) 
inhibit only SphK activity, but high doses inhibit PKC as well (Edsall et al, 
1998). Therefore, DMS can still be used to study SphK, provided the effective 
dose is kept low. For example, DMS was used in the cloning of SphK2 study, 
to study purified SphK2 activity (Liu et al, 2000). However, both DMS and 
TMS are not likely to be suitable therapeutic agents because the effective 
doses of DMS and TMS for cancer therapy are too high, with several doses of 
approximately 0.1-0.3mg/mouse required (Park et al, 1994). Such high doses 
are associated with severe side effects such as hemolysis and hemoglobinuria 
(Park et al, 1994).  
As mentioned previously, SphK1 and SphK2 serve opposing biological 
roles in cell survival (Maceyka et al, 2005), with SphK1 being predominantly 





pro-survival and SphK2 being both pro-survival/apoptotic depending on the 
cellular context. Gene knockout studies have shown that the double knockout 
mice are embryonic lethal (Mizugishi et al, 2005). Single SphK1 or SphK2 
knockout mice can still survive due to the isoforms compensating for each 
other (Allende et al, 2004; Mizugishi et al, 2005). Therefore, pan-SphK 
inhibitors are not useful for studying the specific functional roles of each 
SphK isoform. 
 
1.5.2 Isoform-selective inhibitors of SphK 
 Isoform-selective inhibitors of SphK developed to date includes SKI-II 
(French et al, 2003; French et al, 2006), ABC294640 (French et al, 2010; 
Maines et al, 2008), SK1-I (Paugh et al, 2008b), F12509a (Kono et al, 2002; 
Kono et al, 2000b), B5354c (Kono et al, 2000a; Kono et al, 2000c), S-15183a 
and b (Kono et al, 2001), SG12 and SG14 (Kim et al, 2005), and Compound 
5c (5c) (Wong et al, 2009). Inhibitors proposed to selectively inhibit SphK1 
are SKI-II, SK1-I, 5c, F12509a, B5354c, S-15183a and b. Inhibitors proposed 
to selectively inhibit SphK1 are ABC294640, SG12 and SG14. 
 SphK1-selective inhibitors: French et al developed chemical 
compounds that inhibited SphK activity non-competitively, thus inhibiting cell 
proliferation and induces apoptosis (French et al, 2003). Compound II (SKI-II) 
was the most selective towards SphK and was further validated in leukemia 
(Ricci et al, 2009), breast cancer (French et al, 2006) and glioblastomas 
(Bektas et al, 2009). However, SKI-II has not been validated in the model of 
colorectal cancer. Although it was proposed to be selective for SphK1, there 
are no studies done yet to prove that it only inhibits SphK1 but not SphK2 





Therefore, the inhibitory effects of SKI-II may not be attributed solely to the 
blockade of SphK1.  
 SKI-I is a SphK1-selective inhibitor developed by Spiegel et al (Paugh 
et al, 2008b). It does not inhibit PKC or SphK2. SKI-I was validated in a 
leukemia model, and found to have potent anti-leukemic activity in vivo. SKI-I 
functions by blocking the S1P-induced cell survival. Nonetheless, SK1-I has 
yet to be validated in a model of colorectal cancer.  
 Compound 5c is a SphK1-selective inhibitor developed in our 
laboratory (Wong et al, 2009). It is an analog of sphingosine and inhibits 
SphK1 via competitive inhibition. 5c does not inhibit PKC or SphK2, even at 
high doses. The efficacy of 5c was compared against the conventional SphK 
inhibitor DMS, and shown to have higher inhibitory efficiency than DMS. 5c 
was validated in a leukemia model using the U937 cell line. At low doses 
(e.g.10μm), 5c demonstrated slight anti-proliferative effects, suggesting its 
potential as an anti-cancer drug. Therefore, in this project, we aim to validate 
the inhibition of Sphk1 using 5c as a potential therapeutic strategy in the 
model of colorectal cancer. 
SphK2-selective inhibitors: French et al also developed another 
group of SphK inhibitors that are orally bioavailable (French et al, 2010; 
Maines et al, 2008). ABC294640 is one of the lead compounds in this group 
and it suppresses the TNF-induced ulcerative colitis (Maines et al, 2008). 









1.5.3 Other ways to inhibit SphK and S1P 
 Besides SphK inhibitors, other agents and methods can be used to 
block the activity of SphK1 and subsequent S1P production. These include the 
use of a S1P receptor antagonist FTY720 (Brinkmann et al, 2002), monoclonal 
S1P antibodies (O'Brien et al, 2009; Visentin et al, 2006) and siRNA 
technology to knock down SphK (Lai et al, 2008a; Lai et al, 2008b; Pushparaj 
et al, 2008). 
 
1.6 The Phosphoinositide-3-kinase/Akt pathway 
 The phosphoinositide 3-kinase (PI3K) pathway plays an important role 
in cancer cell growth and survival. Protein Kinase B (PKB/Akt) is the major 
effector of PI3K. Upon stimulation by growth factors, PI3K phosphorylates 
the lipid phosphatidylinositol-4,5-biphosphate (PIP2) to phosphatidylinositol-
3,4,5-triphosphate (PIP3) at the plasma membrane. This phosphorylation can 
be reversed by PIP3 phosphastase (PTEN). PIP3 produced binds the pleckstrin 
homology (PH) domain of Akt and recruits Akt to the plasma membrane. This 
induces a conformational change that relieves the inhibitory effect of the PH 
domain on Akt activity. Akt is then phosphorylated by 3-phosphoinositide-
dependent kinase (PDK-1) at the threonine residue 308 (Thr308), and 
subsequently phosphorylated by PDK-2 at the serine residue 473 (Ser473) to 
be fully activated (Vivanco & Sawyers, 2002) (Figure D). Activated Akt 
amplifies downstream signaling pathways by phosphorylating key proteins. 
Activated Akt is important in the regulation of cell death, proliferation 
and growth of cancer cells (Figure D). Akt inhibits cell death by 
phosphorylating pro-apoptotic proteins such as BAD, pro-caspase 9 and the 





foxhead box proteins (FOXO), thereby blocking their activity (Carnero, 2010). 
Akt phosphorylates Mdm2, which increases the degradation of p53 (Carnero, 
2010). Akt promotes cell proliferation by driving cell cycle progression. Akt 
phosphorylates the CDK inhibitors p21Cip1 and p27Kip1, promoting their 
cytosolic localization to prevent them from exerting inhibitory effects on the 
cell cycle. Akt further regulates nutrient uptake and metabolism, and cross-
activate other survival pathways such as NFкB to promote cell survival 
(Carnero, 2010). Akt also regulates cell growth by directly activating the 
mammalian target of rapamycin (mTOR), which regulates biogenesis 
(Vivanco & Sawyers, 2002). Therefore, the PI3K/Akt pathway plays a key 
role in promoting the development of tumors. This is further evident from the 
frequent gain function of PI3K mutations (Lee et al, 2005) and the loss of 
PTEN (Ali et al, 1999) in a wide spectrum of human cancers. 
 The PI3K/Akt pathway not only promotes tumorigenesis, it also 
influences how cancer cells respond to anti-cancer treatment such as 
radiotherapy and chemotherapy (Huang & Hung, 2009). For example, 
chemotherapeutic drugs such as cisplatin, etoposide, paclitaxel, doxorubicin 
and daunorubicin have been shown to elevate Akt levels in various cancer 
models (Huang & Hung, 2009). Akt confers resistance to these drugs through 
its pro-survival effects mentioned above. Increased expression of Akt, as well 
as decreased expression of PTEN, prognosticate for poor survival in 
endometrial cancer patients (Terakawa et al, 2003). Developing 
chemotherapeutic drugs that inhibit Akt activity is therefore a potential 
therapeutic strategy to treat cancer. 







Figure D. The PI3K/Akt signaling pathway 
Upon stimulation by growth factors, PI3K phosphorylates the lipid 
phosphatidylinositol-4,5-biphosphate (PIP2) to phosphatidylinositol-3,4,5-
triphosphate (PIP3) at the plasma membrane. This phosphorylation is reversed 
by PIP3 phosphastase PTEN. PIP3 in turn binds the pleckstrin homology (PH) 
domain of Akt and recruits Akt to the plasma membrane. This induces a 
conformational change that relieves the inhibitory effect of the PH domain. 
Akt is then phosphorylated by 3-phosphoinositide-dependent kinase (PDK-1) 
at the threonine residue 308 (Thr308), and subsequent phosphorylation by 
PDK-2 at the serine residue 473 (Ser473) to be fully activated. Activated Akt 
exerts its pro-survival effects by acting on downstream players such as BAD, 
forkhead family of transcription factors (FKHR), NFκB, GSK3β, mTOR and 
MDM2. (Reprinted from Nature Reviews Cancer, Vol 2, Vivanco I and 
Sawyers CL, PI3K signaling: the big picture, Page 489-501., Copyright 









1.6.1 The PI3K/Akt pathway in colorectal cancer 
 The PI3K/Akt pathway is very well-established in colorectal cancer, 
and has been implicated in obesity-induced colorectal cancer model (Huang & 
Chen, 2009). The catalytic subunit of PI3K, PIK3CA was found to be mutated 
in colorectal cancer (Samuels et al, 2004). This gain-of-function mutation was 
also found in other cancer models.  
Effect of PIK3CA mutation in colorectal cancer: In colorectal 
cancer, the PIK3CA mutation increased Akt activation (Samuels et al, 2004). 
In vitro, this leads to increased tumor growth (even under serum deprivation 
conditions), and increased migration and invasion rates. In vivo, there is 
increased subcutaneous growth in mice and increased metastasis. PIK3CA 
mutations also induce the lack of response to chemotherapeutic drugs such as 
cetuximab and panitumumab (Jhawer et al, 2008; Loupakis et al, 2009).  
 Role of Akt in colorectal cancer: Whilst there are 3 Akt isoforms 
(Akt1-3) in humans, Akt1 appears to be the predominant Akt isoform in 
colorectal tumors (Samuels et al, 2004). Clinical studies revealed that Akt is 
hyperphosphorylated in metastatic colorectal cancer patients (Roy et al, 2002). 
The use of PI3K inhibitors such as LY294002 (LY29) has been demonstrated 
to suppress colorectal tumor cell growth in vitro (Samuels et al, 2004). Putting 
these findings together, the PI3K/Akt pathway is an attractive therapeutic 
target for the treatment of colorectal cancer. 
 
1.6.2 The link between Akt and SphK1 in cancer 
The link between SphK1 and Akt has been established in several 
models of cell proliferation (Ader et al, 2008; Dayon et al, 2009; Francy et al, 





2007; Kapitonov et al, 2009; Le Scolan et al, 2005; Nemoto et al, 2009; 
Radeff-Huang et al, 2007). These studies have suggested that SphK1 can 
either upstream or downstream of Akt, indicating that SphK1 and Akt are 
closely inter-linked in the pro-survival pathways. 
PI3K/Akt regulates SphK1 activity: In human coronary artery 
smooth muscle cells, PDGF activates PI3K/Akt2 that in turn activates 
downstream SphK1 to promote cell growth (Francy et al, 2007). In prostate 
cancer, the hormone androgen activates PI3K/Akt that in turn activates SphK1 
to promote DNA synthesis and cell proliferation (Dayon et al, 2009).  
SphK1 regulates PI3K/Akt: In leukemia, SphK1 activates 
downstream Akt to give cells a growth advantage and resistance to apoptosis 
during serum deprivation (Le Scolan et al, 2005). In glioblastoma, SphK1 can 
be activated by both TNFα and serum respectively. This leads to the activation 
of Akt and subsequent increase in cell proliferation (Kapitonov et al, 2009; 
Radeff-Huang et al, 2007). Under hypoxic conditions, SphK1 also activates 
Akt to induce HIF-1α that is the major regulator of hypoxia (Ader et al, 2008).  
 Relationship between SphK1 and Akt in colorectal cancer: 
Nonetheless, despite the numerous studies establishing the link between 
SphK1 and Akt in cancer, in colorectal cancer, there are only preliminary data 
linking SphK1 to Akt (Nemoto et al, 2009). Nemoto et al showed that 
treatment of colorectal cancer cells with the anti-cancer drug oxaliplatin 
activates both survival pathways mediated by SphK1 and Akt, thus 
contributing to oxaliplatin resistance (Nemoto et al, 2009). The inhibition of 
SphK activity further down-regulates the activation of Akt and sensitizes 
cancer cells to oxaliplatin. However, this paper points out that the inhibitor 





used (SKI) is non-selective for the SphK-isoforms, thus it is unclear if drug 
resistance is conferred specifically by the SphK1 isoform.  
 
1.7 Protein kinase C 
Protein kinase C (PKC) is an important signaling protein activated in 
the presence of exogenous phorbol esters or the endogenous activator 
diacylglycerol (DAG). DAG is produced in the presence of upstream players 
such as PI3K, phospholipase C (PLC), PLD and phospholipase A2 (PLA2). 
Briefly, PIP2 can be hydrolyzed by PLC to inositol 1,4,5-triphosphate (IP3) 
and DAG. Phosphotidylcholine (PC) can also be hydrolyzed to PLD and 
PLA2, which in turn produces DAG. These accumulations of DAG lead to 
PKC activation (Nakamura & Nishizuka, 1994). 
Regulation of PKC activity: There are 11 PKC isoforms in humans 
and they are sub-divided into 3 families (classical/conventional, novel, 
atypical) based on their regulatory domains (Podar et al, 2007) (Figure E). 
Classical PKCs (cPKCs) include PKCα, PKCβI, PKCβII and PKCγ. Novel 
PKCs (nPKCs) inclu d e PKCδ, PKCε, PKCη, PKCθ and  PKCμ. Atypical 
PKCs (aPKC) in clu d e PKCζ and PKCι/λ. PKCs h ave 4 conserved d omain s 
(C1-C4). The regulatory domain, which regulates the enzymatic activity of 
PKC, is found at the N-terminus. For cPKCs, the regulatory domain consists 
of the C1 and C2 domains. The C1 domain allows cPKCs to bind to DAG and 
the C2 domain allows binding to calcium (Ca2+). Therefore, cPKCs are 
activated by both DAG and Ca2+. On the other hand, the regulatory domain of 
nPKCs consists of only the C1 domain which is activated by DAG but not 
Ca2+. For aPKCs, the regulatory domain consists of an altered C1 domain 





which is activated by PDK-1 (see below) but not by DAG or Ca2+. Besides the 
C1 and C2 domains, all PKCs contain the C3 and C4 domains found at the C 
terminus. The C3 domain contains the ATP binding consensus sequence. The 
C4 domain, known as the catalytic domain, allows PKCs to bind to their 
respective substrates. All PKCs also contain a pseudosubstrate binding 
sequence (autoinhibitory) and an activation loop (Podar et al, 2007).  
 
Figure E. The structure of PKCs 
PKCs have 4 conserved domains (C1-C4). The regulatory domain, which 
regulates the enzymatic activity of PKC, is found at the N-terminus. For 
cPKCs, the regulatory domain consists of the C1 and C2 domains. The C1 
domain contains the DAG binding site. The C2 domain contains the Ca2+ 
binding site. For nPKCs, the regulatory domain only consists of the C1 
domain. For aPKCs, the regulatory domain consists of an altered C1 domain. 
Besides the C1 and C2 domains, all PKCs contain the C3 and C4 domains 
found at the C terminus. The C3 domain contains the ATP binding consensus 
sequence. The C4 domain, known as the catalytic domain, allows substrate 
binding. There is also an autoinhibitory pseudosubstrate binding sequence and 
an activation loop. DAG, diacylglycerol. 





Activation of PKC: Due to the differences in their regulatory 
domains, the 3 families of PKCs have slightly different activation 
mechanisms. Both cPKCs and nPKCs require DAG and phosphatidylserine 
(PS) for full activation (Figure F). In response to growth factor stimulation, 
PKCs are first recruited to the plasma membrane by PDK-1, which 
phosphorylates PKC at its activation loop. This leads to the immediate auto-
phosphorylation of cPKC at the C1 and C2 domains; and nPKCs at the C1 
domain. The phosphorylated PKC is released back into the cytosol and 
remains inactive due to binding of the auto-inhibitory pseudosubstrate. In the 
presence of DAG and phosphatidylserine (PS), PKC is again recruited to the 
plasma membrane. This time, the pseudosubstrate is expelled from the PKC 
protein, thus allowing PKC to be fully activated. For cPKCs, there is an 
additional requirement for Ca2+ to be present before the pseudosubstrate can be 
expelled (Dempsey et al, 2000). However, for aPKCs, the activation 
mechanism differs and does not require DAG, Ca2+ and PS (Chou et al, 1998; 
Hirai & Chida, 2003; Zhou et al, 1994) (Figure G). Upon phosphorylation by 
PDK-1 at the activation loop, aPKCs do not return to the cytosol. Instead, it 
interacts with PIP3, which releases the pseudosubstrate and allows aPKCs to 
be fully activated.  
Although they have similar homology, the 11 PKC isoforms serve very 
distinct biological roles in humans. In the study of cancer progression, up-
regulation of these PKC isoforms has diverse effects, depending on cellular 
context and surrounding players (Podar et al, 2007). For example, PKCα and 
PKCδ can be either pro- or anti-proliferative in different cancer models. 
Therefore, the PKC family is very interesting and holds huge therapeutic 





potential in the field of anti-cancer therapy. However, one must take into 
consideration that we cannot study PKC activity as a whole. It is important for 




Figure F. The activation of cPKCs and nPKCs. 
cPKCs and nPKCs are first recruited to the plasma membrane by PDK-1, 
which phosphorylates PKC at its activation loop. This leads to the immediate 
autophosphorylation of cPKC at the C1 and C2 domains; and nPKCs at the C1 
domain. The phosphorylated PKC is released back into the cytosol and 
remains inactive due to binding of the autoinhibitory pseudosubstrate. In the 
presence of DAG and PS, PKC is again recruited to the plasma membrane. 
This time, the pseudosubstrate is expelled from the PKC protein, thus allowing 
PKC to be fully activated. For cPKCs, there is an additional requirement for 
Ca2+ to be present before the pseudosubstrate can be expelled. PS, 



















Figure G. The activation of aPKCs. 
Upon phosphorylation by PDK-1 at the activation loop, aPKCs do not return 
to the cytosol. Instead, it interacts with phosphatidylinositol-3,4,5-triphosphate 
(PIP3), which releases the pseudosubstrate and allow aPKCs to be fully 














  PKC inhibitors: Several inhibitors have been developed to facilitate 
the study of PKCs (Shen, 2003). General PKC inhibitors include HA1004, 
staurosporine, calphostin C and safingol. These inhibitors interfere with the 
ATP binding site on PKCs but are not isoform-specific. Partial isoform-
specific inhibitors have been synthesized for certain isoforms such as cPKCs 
and nPKCs. For example, UCN-01 and CGP41251 are selective inhibitors for 
cPKCs. Bisindolymaleimides derived from staurosporine such as Bis I inhibit 
cPKCs at very low doses (0.01μm), inhibit nPKCs at moderate doses (0.1μM) 
and inhibit aPKCs at very high doses (6-10μM) (Martiny-Baron et al, 1993; 
Toullec et al, 1991). Thus, careful manipulation of the Bis I allows us to study 
specific PKCs. More highly-specific inhibitors include the PKCβ-selective 
inhibitors LY333531 and LY317615 (Enzastaurin), as well as the PKCδ-
selective inhibitor, rottlerin. Nonetheless, more PKC isoform-specific 
inhibitors will need to be developed to enable a more in-depth investigation 
into the specific roles of each PKC isoform. 
 
1.7.1 PKCs in Cancer 
PKCβII and PKCι: PKCβII and PKCι are two well-studied PKC 
isoforms in colorectal cancer. PKCβII is up-regulated in the human colorectal 
tumor tissues and correlates with poor survival prognosis of patients (Spindler 
et al, 2009). In vitro, PKCβII has been shown to be involved in the 
azoxymethane-induced colon tumorigenesis (Fields et al, 2009; Gökmen-Polar 
et al, 2001; Liu et al, 2004; Murray et al, 1999). PKCβII is up-regulated upon 
addition of azoxymethane (Gökmen-Polar et al, 2001). Overexpression and 
knockdown studies showed that PKCβII is important for inducing colonic 





hyperproliferation and increasing sensitivity of cells to azoxymethane (Liu et 
al, 2004; Murray et al, 1999). PKCβII exerts its pro-survival effects by 
phosphorylating glycogen synthase kinase 3β (GSK-3β), which results in the 
inhibition of adenomatous polyposis coli (APC) and prevents the degradation 
of β-catenin. Accumulation of β-catenin stimulates proliferation (Murray et al, 
1999). PKCβII is suggested to be a potential chemopreventive target.   
Inhibition of PKCβII using Enzastaurin inhibits β-catenin accumulation, 
thereby reducing azoxymethane-induced tumor initiation and progression 
(Fields et al, 2009).  
PKCι has been validated as an oncogene in non-small cell lung cancer 
(NSCLC) (Regala et al, 2005a; Regala et al, 2005b), pancreatic cancer (Scotti 
et al, 2010), leukemia (Murray & Fields, 1997) and colorectal cancer (Murray 
et al, 2004). In NSCLC and pancreatic cancer, PKCι was up-regulated and 
correlates with poor survival prognosis in patients (Regala et al, 2005a; Regala 
et al, 2005b; Scotti et al, 2010; Stallings-Mann et al, 2006). It promotes 
tumorigenesis by regulating downstream Rac-1 (Regala et al, 2005a; Regala et 
al, 2005b; Scotti et al, 2010). PKCι promotes the survival of tumor cells such 
as leukemia cells upon stress and drug treatments (Murray & Fields, 1997). 
Importantly, PKCι drives the transformation of colon carcinoma cells from 
benign to malignant state upon induction by the oncogene Ras (Murray et al, 
2004). 
An interesting study by Murray and group has shown that PKCβII and 
PKCι are collaborating partners in the development of colorectal cancer 
(Murray et al, 2009). Using the azoxymethane-induced colorectal cancer 
model, it was shown that PKCβII is required for the initiation and growth of 





colon adenomas. PKCι, on the other hand, is required for the progression from 
colon adenomas to more malignant colon adenocarcinomas. 
Several other PKC isoforms have been suggested to play a role in 
cancer progression, but their exact functions and mechanisms remains unclear 
and controversial. These isoforms include PKCδ, PKCε and PKCζ.  
 PKCδ: PKCδ is an interesting PKC isoform which has been shown to 
have both tumor-suppressive and tumor-promoting roles. The tumor-
suppressive roles of PKCδ are supported by the following evidence in several 
types of cells including colorectal cancer cells and fibroblasts. In a colorectal 
cancer model, PKCδ was fou nd  to be d own-regulated (Cerda et al, 2001). 
Overexpression of PKCδ induces G1 cell cycle arrest by down-regulating 
cyclin D and cyclin E expression, and increasing the inhibitory effects of CDK 
inhibitors p21Cip1 and p27Kip1. Overexp ression of PKCδ also p romo tes 
apoptosis by up-regulating pro-apoptotic Bax and down-regulating anti-
apoptotic Bcl2. Interestingly, in fibroblasts, PKCδ and PKCε demonstrated 
opposing oncogenic effects (Mischak et al, 1993). PKCδ suppresses the 
growth of fibroblasts in vitro, while PKCε promotes soft agar colony 
formation in vitro as well as tumor formation in vivo.  
 However, PKCδ may also be involved in pro-survival mechanisms. In 
a breast cancer model, PKCδ promotes the survival of breast cancer cells by 
suppressing the ERK1/2 pathway (Lønne et al, 2009). It even cooperated with 
PKCε to promote breast cancer cell proliferation upon the addition of 
bradykinin (Greco et al, 2006). Therefore, caution should be taken when 
interpreting the functions of PKCδ, as it has both pro-apoptotic (Cerda et al, 
2001; Mischak et al, 1993) and pro-survival functions (Greco et al, 2006; 





Lønne et al, 2009), depending on the cell line and cancer model used. More 
work needs to be done to understand the roles of PKCδ in cancer. 
PKCζ: PKCζ has been shown to be pro-apoptotic in many cancer 
models, including colorectal cancer (Mustafi et al, 2006) and breast cancer 
(Mao et al, 2000). PKCζ is d own-regulated in the azoxymethane-induced 
colon tumorigenesis (Mustafi et al, 2006). Overexpression of PKCζ inhibits 
colorectal cancer cell proliferation and soft agar colony formation, at the same 
time promoting apoptosis and differentiation. Interestingly, PKCζ levels 
correlate with the poor survival prognosis of ovarian cancer patients 
(Nazarenko et al, 2010). However, PKCζ levels in the ovarian cancer cells in 
vitro is elevated by the tumor suppressor HRLS3 via protein phosphatase 2A 
(PP2A), as well as by okadaic acid, to induce apoptosis. Okadaic acid-
dependent apoptosis is a characteristic feature of ovarian cancer cells. 
Nazarenko et al thus argued that the high expression levels of PKCζ in ovarian 
cancer patients do not necessarily correlates with the activation status of the 
kinase and they hypothesized that PKCζ may act as a survival control protein 
in ovarian cancer. This means that in the presence of activated tumor 
suppressor HRLS3/PP2A, PKCζ will be activated to induce apoptosis in the 
ovarian cancer cells.  
 
1.7.2 The link between PKC and Sphingolipids 
 The link between PKC and sphingolipids has been demonstrated in 
several studies (Chmura et al, 1997a; Cuvillier et al, 1996; Shu et al, 2002; 
Spiegel et al, 1998). Evidence indicates that PKC regulates the activities of 
SphK1 and sphingolipids such as S1P. PKC induces the translocation of 





SphK1 to the plasma membrane, a key step in the activation of SphK1, and 
promotes the secretion of S1P out of cells (Johnson et al, 2002). As mentioned 
previously, TNF induces ceramide production that induces apoptosis in cells. 
These cells may be rescued from TNF-induced apoptosis by the stimulation of 
PKC which in turn activates SphK, resulting in increased levels of pro-
survival S1P (Cuvillier et al, 1996). In endothelial cells, VEGF stimulates 
PKC, leading to activation of SphK1 to induce endothelial cell growth (Shu et 
al, 2002). The bioactive sphingolipids in turn influence the activity of PKC by 
indirectly modulating the levels of DAG (Spiegel et al, 1998). DAG releases 
the auto-inhibitory pseudosubstrate from classical and novel PKC proteins, 
allowing them to be fully activated. Ceramide inhibits DAG generation by 
inhibiting upstream phospholipases such as PLD, while S1P promotes DAG 
generation by inducing PLD activity. Although there is a clear link between 
PKC and sphingolipids, the identification of PKC isoforms linked to these 
sphingolipids is still unclear. 
 Pro-survival PKC isoforms interacting with sphingolipids: Pro-
survival PKC isoforms that regulate the sphingolipid rheostat include the 
classical and novel PKCs. They appear to promote tumor survival by favoring 
the production of S1P and reducing ceramide levels (Chmura et al, 1997a). 
Inhibition of these PKC isoforms in vivo enhances the killing effects of 
radiation therapy and promotes tumor regression via the activation of neutral 
sphingomyelinase, which is required for production of the pro-apoptotic 
ceramide. In vitro, inhibition of these PKC isoforms induces DNA 
fragmentation and apoptosis (Chmura et al, 1996). Thus, activation of classical 





and novel PKCs in cancer cells render them to be more resistant to 
radiotherapy. 
Pro-apoptotic PKC isoforms interacting with sphingolipids: Pro-
apoptotic PKC isoforms have been found to interact with pathways mediated 
by ceramide, and these include PKCδ (Zeidan & Hannun, 2007; Zeidan et al, 
2008) and PKCζ (Bourbon et al, 2000; Fox et al, 2007; Wang et al, 2005). 
Upon exposure to DNA d amagin g  ag ents su ch as ultrav iolet rays, PKCδ is 
activated, leading increased acid sphingomyelinase activity which upregulates 
pro-apoptotic ceramide levels (Zeidan & Hannun, 2007; Zeidan et al, 2008).  
PKCζ appears to have contradictory roles - it may promote growth 
arrest as well as survival. Importantly, there is evidence to indicate that PKCζ 
is activated by ceramide to initiate these downstream survival effects. In 
vascular smooth muscle cells, ceramide-activated PKCζ activates the stress-
activated protein kinase (SAPK) cascade, leading to growth arrest (Bourbon et 
al, 2000). Furthermore, the ceramide-activated PKCζ inactivates Akt, an 
important pro-survival protein, thereby potentiating growth arrest mechanisms 
(Fox et al, 2007).  
However, ceramide-activated PKCζ is also reported to be pro-survival. 
In differentiating embryonic stem cells, ceramide-activated PKCζ induces cell 
survival. These pro-survival effects of PKCζ may be inhibited by the binding 
of ceramide to the endogenous PKCζ inhibitor, prostate apoptosis response-4 
(PAR4)  (Wang et al, 2005). This illustrates the complex regulation of PKCζ 
by ceramide.  
 
 





1.7.3 The link between PKC and the PI3K/Akt pathway 
PKCs are potentially linked to the PI3K/Akt pathway because both 
PKCs and Akt are substrates of PDK-1. Activation of PKCs and Akt first 
require phosphorylation by PDK-1. PI3K regulates the production of DAG, 
which is required for the activation of cPKCs and nPKCs. It also 
phosphorylates PIP2 to PIP3, which is required for the activation of aPKCs. 
PI3K regulates the activation of PKCδ and PKCζ via the regulatory domain of 
PDK-1 (Chou et al, 1998; Le Good et al, 1998). In particular, PKCζ negatively 
regulates Akt (Doornbos et al, 1999; Mao et al, 2000). PKCζ interacts with 
Akt (Doornbos et al, 1999) and inhibits its phosphorylation, thereby limiting 
EGF-induced pro-survival signaling (Mao et al, 2000). Vice versa, inhibition 
of PKCζ with h igh doses of Bis I increases Akt phosphorylation (Mao et al, 
2000). Therefore, pro-apoptotic PKCζ potentially inhibits Akt activity to 
promote apoptosis. Pro-survival PKCs are thus likely to interact positively 
with Akt to promote survival.   
  





1.8 AIMS OF PROJECT 
In this research project, we seek to validate the pro-survival role of SphK1 and 
to investigate its therapeutic potential in colorectal cancer.  
 
The key aims of this project are as follows: 
 
i. Investigate the expression of SphK1 in colorectal cancer cell lines 
and patients’ colorectal tumor tissues. 
 
SphK1 protein levels has been shown to be up-regulated in many 
cancer models such as brain, prostate, leukemia, breast, pancreatic, gastric 
cancer (Introduction section 1.3.2). This up-regulation of SphK1 expression 
further translates to clinical relevance in several studies, whereby high SphK1 
expression correlates with poor survival prognosis of brain, breast, pancreatic, 
gastric cancer patients. 
However, in colorectal cancer, the expression of SphK1 in the 
colorectal cancer cell lines and patients’ tumor tissues is not well-studied. 
Nemoto et al screened only 3 colorectal cancer cell lines (HCT116, LoVo and 
RKO) for their SphK1 protein expression and activity levels, and found that 
RKO had the highest SphK1 protein expression and activity level (Nemoto et 
al, 2009). Kawamori et al did an analysis of 61 mixed human colonic tumors 
comprising malignant adenocarcinomas as well as the more benign adenomas, 
and showed that SphK1 expression was higher in tumors compared to normal 
mucosa, as well as in malignant adenocarcinomas compared to adenomas 
(Kawamori et al, 2006). However, there were no correlations made with 





clinico-pathological parameters such as the length of survival of cancer 
patients. 
The aim of this project is to investigate the correlation of SphK1 
expression in malignant colorectal tumors with various clinico-pathological 
parameters. To achieve this, we analysed the expression of SphK1 protein in 
human colorectal tumor tissues comprising mainly of malignant 
adenocarcinomas, as well as in a panel of colorectal cancer cell lines 
(HCT116, RKO, SW480 and SW620).  
 
ii. Investigate whether the blockade of SphK1 leads to colorectal 
cancer cell growth arrest or apoptosis. 
 
Previous studies have shown that in mice, SphK1 is important in the 
progression of colorectal tumors induced by azoxymethane (Kawamori et al, 
2009; Kohno et al, 2006). SphK1 knockout mice had reduced cell proliferation 
and increased apoptosis, eventually leading to size reduction of polyps.  
In this project, we are interested in the serum-driven SphK1 activity 
that promotes survival of colorectal cancer cells in vitro. Colorectal cancer cell 
lines (HCT116, RKO, SW480 and SW620) will be stimulated with fetal 
bovine serum (FBS), to investigate the effect of SphK1 activity on cell 
survival. In addition, SphK1 activity will be blocked with a SphK1-specific 
inhibitor Compound 5c (Wong et al, 2009), to investigate if this leads to 
colorectal cancer cell growth arrest or apoptosis. 
 
 





iii. To use SphK1 inhibitors alone and together with other known 
chemotherapeutic drugs to improve the effectiveness of treating 
colorectal cancer. 
 
The up-regulation of SphK1 levels is a mechanism employed in 
various cancer cells to resist chemotherapeutic insults (Akao et al, 2006; 
Bonhoure et al, 2008; Dayon et al, 2009; Pchejetski et al, 2005). In colorectal 
cancer, Nemoto et al demonstrated that the inhibition of SphK activity 
overcomes the resistance of cancer cells to oxaliplatin treatment (Nemoto et al, 
2009). However, it is not clear which SphK isoform accounts for this drug 
resistance. Since SphK1 appears to be the oncogenic isoform of SphK that 
promotes cancer cell survival, one of the aims of this project is to validate the 
therapeutic potential of inhibiting SphK1 activity to treat colorectal cancer. 
In addition, we are interested in investigating the potential of the 
‘double hit’ strategy proposed by Mocellin et al to treat colorectal cancer 
(Mocellin et al, 2005). The ‘double hit’ strategy refers to the combination of 
chemotherapeutic drugs that induces cytotoxicity and ‘targeted drugs’ that 
attacks specific molecular pathways, that may potentially overcome the issue 
of drug resistance in colorectal cancer cells. Therefore, in this project, we are 
interested in investigating the effectiveness of combining known 
chemotherapeutic drugs such as 5-FU (that induces cytotoxicity) with SphK1 
inhibition (to attack SphK1-linked survival pathways) to induce colorectal 
cancer cell death. 
 





iv. To investigate novel molecular mechanisms regulated by SphK1 in 
colorectal cancer cell survival. 
 
Several studies have suggested the link between SphK1 and Akt (Ader 
et al, 2008; Dayon et al, 2009; Francy et al, 2007; Kapitonov et al, 2009; Le 
Scolan et al, 2005; Nemoto et al, 2009; Radeff-Huang et al, 2007) and PKCs 
(Chmura et al, 1997a; Cuvillier et al, 1996; Shu et al, 2002; Spiegel et al, 
1998) respectively. In different disease models, SphK1 may be found either 
upstream or downstream of Akt. However, in colorectal cancer, there is only 
preliminary evidence suggesting that SphK regulates downstream Akt activity 
(Nemoto et al, 2009). More work needs to be done to find out which SphK 
isoform regulates Akt and how it regulates Akt to promote cell survival.  
The PI3K/Akt pathway is very well-established in colorectal cancer. It 
is an important pro-survival pathway that promotes tumorigenesis, and 
influences how cancer cells respond to anti-cancer treatment such as 
radiotherapy and chemotherapy (Huang & Hung, 2009). Gain-of-function 
mutations in the catalytic subunit of PI3K (PIK3CA) increase Akt activation, 
leading to increased tumor growth rates and metastasis (Samuels et al, 2004). 
It further contributes to cancer cells resistance to chemotherapeutic drugs such 
as cetuximab and panitumumab (Jhawer et al, 2008; Loupakis et al, 2009). 
Given the importance of the PI3K/Akt pathway in colorectal cancer, it is 
important to elucidate novel signaling pathways downstream of PI3K, and 
these novel signaling players downstream of PI3K may be targeted as 
therapeutic strategies to kill colorectal cancer cells. 





Other studies have shown that PKC regulates SphK1 activity (Johnson 
et al, 2002) and several pro-survival PKC isoforms promote tumor survival by 
up-regulating S1P levels (Chmura et al, 1997a). Nonetheless, S1P is also 
required for the activation of classical and novel PKCs by elevating DAG 
levels (Spiegel et al, 1998). In colorectal cancer, a few PKC isoforms have 
been suggested to be important for cancer cell survival (PKCβII, PKCι, PKCδ, 
PKCζ), but their link to SphK1 is yet unclear. Therefore, we are keen to 
investigate which PKC isoforms interact with SphK1 to promote colorectal 
cancer cell survival. We hypothesize that by elucidating the signaling 
relationship between these pro-survival signaling players (SphK1, Akt, PKCs), 
we will further expand the understanding of how colorectal cancer cells evade 




















Materials & Methods 
All reagents and chemicals unless stated otherwise were bought from Sigma-
Aldrich. 
 
2.1 Solutions and Buffers 
• RIPA buffer for total cell lysate preparation: 50mM Tris-HCl, pH7.4; 
1% NP-40; 0.25% Na-deoxycholate; 150mM NaCl; 1mM EDTA 
• Resolving gel for SDS-PAGE: distilled water, 30% acrylamide/bis, 
1.5M Tris (pH 8.8), 10% SDS, 10% APS, TEMED 
• Stacking gel for SDS-PAGE: distilled water, 30% acrylamide/bis, 
1.0M Tris (pH 6.8), 10% SDS, 10% APS, TEMED 
• Running buffer for SDS-PAGE: 25mM Tris base, 250mM glycine (pH 
8.3), 0.1% SDS 
• Transfer buffer for SDS-PAGE: 25mM Tris base, 250mM glycine (pH 
8.3), 0.025% SDS 
• 1xSDS gel-loading buffer for SDS-PAGE: 50mM Tris-HCl (pH 6.8), 
100mM β-mercaptoethanol, 2% SDS, 0.1% bromophenol blue, 10% 
glycerol 
• Washing buffer for SDS-PAGE: 1x TBS, 0.1% Tween-20 
• 1x TBS for SDS-PAGE: 137mM NaCl, 20mM Tris-HCl (pH 7.6) 
• SphK buffer for measurement of SphK activity: 50mM 4-(2-
hydroxyethyl)piperazine-1-ethanesulfonic acid (pH 7.4), 15mM 
MgCl2, 0.005% Triton X-100, 10mM KCl 
 





2.2 Immunohistochemistry  
Tissue microarray slides were deparaffinized with xylene, and rehydrated with 
graded alcohol. Slides were then heated with the antigen unmasking solution 
(low pH) (Vector Laboratories, USA) for 10 minutes and allowed to cool. The 
DakoCytomation EnVision®+ System–HRP (AEC) kit (Dakocytomation, 
USA) was used to stain the slides. Briefly, after blocking endogenous 
peroxidase with hydrogen peroxide for 10 minutes, slides were incubated with 
the respective primary antibodies (Rabbit anti-SphK1 (Abcam, USA)) in 0.5% 
BSA in TBS for 1 hour on bench. Secondary antibody incubation followed 
thereafter for 30 minutes. Tissue sections were counterstained with 
hematoxylin.  
 
2.3 Cell Lines  
Human cell lines HCT116, SW480, SW620 and RKO were purchased from 
American Type Culture Collection (ATCC, USA). HCT116 cells were 
cultured in the McCoy 5A Modified Medium containing 10% fetal bovine 
serum (FBS) (Gibco, USA). SW480, SW620 and RKO cells were cultured in 
the Dulbecco's Modified Eagle Medium (DMEM) containing 10% FBS.  
 
2.4 MTT Cell Viability Assay 
Cells (2x104/well in 100ul) were plated in 96-well plates and cultured with 1% 
FBS for 18 hours. Subsequently, respective drugs were added and cells were 
incubated for another 48 hours in 10% FBS. Dimethylsphingosine (DMSO) 
was added into the cultures as a vehicle control. Cell viability was determined 
with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide 





(MTT) dye reduction assay as previously described (104).  Results are 
expressed as a percentage of live cells relative to the untreated control at the 
indicated time. 
 
2.5 Stimulation of cells 
Cells (1x106/well in 2ml) were plated in 6-well plates with 1% FBS for 18 
hours. Subsequently, cells were pretreated with inhibitors for 60 minutes 
before stimulation with serum (10% FBS). Reaction was stopped at various 
time-points with ice-cold 1x Phosphate Buffered Saline (PBS). Cell pellets are 
collected for subsequent experiments described below. For western blot 
analysis and the measurement of SphK activity, cell lysates were collected by 
lysing cells in a master-mix of RIPA buffer with protease and phosphatase 
inhibitors (Roche, USA). Protein concentration was measured using the 
Bradford reagent (Biorad, USA).  
 
2.6 Western Blot Analysis 
Equal amounts of protein lysate (15-40µg) are separated by SDS-PAGE and 
then transblotted to PVDF membranes (Millipore, USA). Blots were incubated 
with the respective primary antibodies - rabbit anti-SphK1 (Cell Signaling 
Technology Inc, USA); rabbit anti-phosphorylated-AktSer473, Thr308 (Cell 
Signaling Technology Inc, USA); rabbit anti-Akt (Santa Cruz Biotechnology 
Inc, USA); mouse anti-PKCδ (BD Biosciences, USA); mouse anti-GAPDH 
(Santa Cruz Biotechnology Inc, USA); rabbit anti-β-tubulin (Santa Cruz 
Biotechnology Inc, USA) overnight followed by appropriate horseradish 
peroxidase-conjugated secondary antibodies (Anti-rabbit IgG HRP (Thermo 





Scientific, USA); anti-mouse IgG HRP (Santa Cruz Biotechnology Inc, 
USA)). Immunocomplexes were visualized by enhanced chemiluminescence 
(Thermo Scientific, USA) on film (Thermo Scientific, USA). 
 
2.7 Measurement of Sphingosine Kinase Activity (Fluorometric 
method) 
Protocol was adapted from Billich and Ettmayer 2004 (Billich & Ettmayer, 
2004). 40μg of protein was incubated in total volumes of 100μl with 20μM of 
15-NBD-Sph (prepared as a complex with BSA) and ATP (1mM) in SphK 
buffer. After incubation for 30 min at 37°C, 100μl 1M potassium phosphate 
buffer, pH 8.5, was added followed by 500μl CHCl3/MeOH 2:1. After brief 
mixing, phases were separated by centrifugation (5 min, 5,000RPM). An 
aliquot (75μl) of the upper aqueous layer was removed and placed into the 
wells of black 96-well polystyrene microplates (Greiner Bio-One, USA), 
followed by 75μl of dimethylformamide (Merck, USA). Fluorescence 
intensity was measured with excitation at 485nm and emission at 535 nm. A 
reaction mixture containing no protein lysate served as blank. 
 
2.8 Measurement of S1P Levels 
S1P levels were analyzed using a S1P competitive ELISA kit (Echelon 
Biosciences) according to the manufacturer’s instructions. Sensitivity of the 
assay was 30 nM. HCT116 cells were plated at a density of 0.5x106 cells per 
well in 12-well plates with 1% FBS for 18 hours. Subsequently, cells were 
pretreated with inhibitors for 60 minutes before stimulation with serum (10% 
FBS). Supernatant were collected for S1P measurement. 





2.9 Immunofluorescence Microscopy 
After serum stimulation, cells were fixed in 3.7% formaldehyde and 
permeabilized in 0.1% Triton X-100. 10,000 cells were cyto-spinned onto 
slides and blocked with 1% bovine serum albumin (BSA) for 10 minutes. 
After blocking, slides were incubated with the respective primary antibodies 
for 90 minutes - rabbit anti-SphK1 (Cell Signaling Technology Inc, USA); 
rabbit anti-PKCζ (Cell Signaling Technology Inc, USA); mouse anti-PKCδ 
(BD Biosciences, USA); mouse anti-PKCε (BD Biosciences, USA), followed 
by Fluorescein isothiocyanate (FITC)-conjugated secondary antibodies for 90 
minutes (Anti-rabbit IgG FITC; anti-mouse IgG FITC). Coverslips were 
mounted onto slides using the Fluorosave mounting reagent (Millipore, USA). 
 
2.10 Cell Cycle Analysis 
Cells (1x106/well in 2ml) were plated in 6-well plates with 1% FBS for 18 
hours. Subsequently, cells were incubated with 5c (doses from 10-100µM) for 
24 hours in the presence of 10% FBS. All samples were harvested and fixed 
with 70% ethanol, followed by suspension in propidium iodide (PI) 
(Invitrogen, USA)/RNase staining buffer solution. Cell cycle anaylsis was 
performed using cell flow cytometer (BD FACSCalibur) and Cell Quest Pro 
Software. 
 
2.11 Annexin V Assay 
Surface expression of phosphatidyl serine was determined by Annexin-V-
Fluos staining kit (Roche, USA). Cells (1x106/well in 2ml) were plated in 6-
well plates with 1% FBS for 18 hours.  Subsequently, cells were incubated 





with 5c (doses from 25-100µM) for 24 and 48 hours in the presence of 10% 
FBS. All samples were harvested and exposed to Annexin V according to 
manufacturer’s instructions. Annexin V staining was determined using cell 
flow cytometer (BD FACSCalibur) and the Cell Quest Pro Software. 
 
2.12 Gene Knockdown by small interfering RNA (siRNA) 
PKCδ siRNA that targets 5’-CAGCAGCAAGTGCAACATCAA-3’ was 
synthesized from Qiagen. The transfection of siRNA was conducted in a 96-
well format (for MTT cell viability assay) or 6-well format (for Western blot 
analysis), using Lipofectamine RNAiMAX (Invitrogen, USA) following the 
manufacturer’s instructions. 10nM of siRNA is used for each transfection. 24 
hours after transfection, the transfection media (Opti-MEM) was replaced with 
complete media to allow cells to recover. For cells in the 6-well format, 24 
hours after recovery, complete media was replaced with 1% FBS-media to 
serum-starve the cells. Following 18 hours of serum-starvation, these cells 
were triggered with 10% FBS and cell pellets were harvested for western blot 
analysis. For cells in the 96-well format, 48 hours after transfection, MTT 
assay was carried out on these cells to measure cell viability. In all 
experiments, the AllStars Negative Control siRNA (Qiagen, USA) was used as 
a negative control sequence. This negative control siRNA has no homology to 
any known mammalian gene. 
 
2.13 Statistical Analysis 
For the in vitro cell line studies, the statistical significance of differences 
between the means of two groups was evaluated using the unpaired Student’s 





t-test. All statistical tests were two-sided and the level of significance was set 
at P<0.05. For the tissue microarray analysis studies, the statistical 
significance of differences between the means of two groups was evaluated 
using the SPSS program (version 15.0 for Windows, SPSS Inc., USA) with 
significance set at the 5% level. The chi-square (χ2) test is used to test for 










Expression of SphK1 in correlation to colorectal cancer 
 
3.1 SphK1 expression in the tumors of colorectal cancer patients  
To investigate the importance of SphK1 in colorectal cancer, we 
ascertained the SphK1 expression in human colorectal tumor tissues of 
patients treated at the National University Health System in Singapore and the 
St John of God HealthCare in Western Australia. In the literature to date, there 
is only 1 study that looked at SphK1 expression in the tumor tissues of 
colorectal cancer patients treated in the United States (Kawamori et al, 2006). 
Analysis of 61 mixed human colonic tumors consisting of adenomas and 
adenocarcinomas showed that SphK1 expression was higher in tumors 
compared to normal mucosa, as well as in malignant adenocarcinomas 
compared to adenomas, suggesting a role for SphK1 in colonic tumorigenesis 
(Kawamori et al, 2006). Thus, we seek to further ascertain the contribution of 
SphK1 to the malignant behavior of colorectal adenocarcinomas.  
 Immunohistochemistry staining of SphK1 expression was performed 
on tissue microarrays (TMAs) containing colorectal cancer cases with 
matched normals obtained from epithelia adjacent to the tumor tissues. A total 
of 732 colorectal tumor cases with 685 matched normals was analysed for 
SphK1 expression. A 4-tier scoring system was used, whereby the intensity of 
SphK1 expression was classified on an increasing scale of 0-3, with ‘0’ being 
undetectable and ‘3’ being the most intensely stained (Fig.1). Consistent with 
the previous study (Kawamori et al, 2006), we observed a significantly higher 
SphK1 expression in colorectal adenocarcinomas compared to the adjacent 





normal tissues, with 55.6% (407 of 732 cases) of tumor tissues exhibiting high 
SphK1 expression (intensity 2-3) (Fig.2). In contrast, the expression of SphK1 
in normal colorectal tissues was predominantly low, with 79.9% (547 of 685 
cases) of tissues exhibiting low staining intensities of 0-1. Analysis of the 
pathological characteristics of tumors revealed a positive correlation between 
SphK1 expression and tumor stage in the combined cohort of 732 cases. Late-
stage tumors (Grade III-IV), associated with the spread to lymph nodes and 
distant metastasis, expressed higher SphK1 levels compared to early-stage 
tumors (Table 1). Further analysis of the pathological characteristics of tumors 
in the Singapore patient cohort revealed a positive correlation between SphK1 
expression and tumor size, with higher SphK1 levels associated with larger 
tumor sizes (Table 2). Importantly, high SphK1 expression was associated 
with poorer survival, with a mean survival difference of 9.9 months (p=0.011, 
Fig.3). The positive correlation between SphK1 expression and tumor size, 
tumor stage and poor survival prognosis strongly suggests a functional role of 


















Fig.1. A 4-tier classification system to score the expression of SphK1 
Immunohistochemistry staining of SphK1 was carried out in both normal and 
tumour tissues. SphK1 expression in tumour tissues was tabulated using the 4-
tier scoring system (0, 1+, 2+, 3+). SphK1 expression was classified as low (0, 



























Fig.2. SphK1 expression is up-regulated in human colorectal tumor 
tissues compared to the normal controls 
Intensity of SphK1 expression in the normal (n=685) versus tumour (n=732) 
tissues. Results are expressed as the percentage of each category over the total 
number of cases. Majority of the tumor tissues had high SphK1 expression, as 
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Fig.3. SphK1 expression correlates with poor survival prognosis of 
colorectal cancer patients  
Survival analysis was carried out on 732 colorectal cancer patient tumor 
tissues, 325 tumor tissues with low SphK1 expression and 407 tissues with 
intermediate to high SphK1 expression. Survival was measured from the date 
of diagnosis until the date from death from gastric cancer, or was censored 
until the date of the last follow-up for non-colon cancer related deaths and 
survivors. The Kaplan-Meier method was used for estimating survival rates 
with the group differences assessed by log-rank test. High SphK1 expression 
correlates to poor survival of the colorectal cancer patients. 









(Total n = 732) 
n 
Low SphK1 
(n = 325) 
High SphK1 
(n = 407) 
Gender    
Male 336 (45.9%) 145 (44.6%) 191 (46.9%) 
Female 396 (54.1%) 180 (55.4%) 216 (53.1%) 
    
Histological grade    
Well/moderately 
differentiated 
677 (92.5%) 302 (92.9%) 375 (92.1%) 
Poorly 
differentiated 
55 (7.5%) 23 (7.1%) 32 (7.9%) 
    
Tumour stage    
I and II 473 (64.6%) 220 (67.7%) 253 (62.2%) 
III and IV 258 (35.4%) 105 (32.3%) 153 (37.8%) 
 
 
Clinical features Odds Ratio (95% CI) 
Test of Significance 
(p-value) 
Gender (female vs male) 1.11 (0.76-1.62) 0.61 
Grade (poor vs well/moderate) 1.5 (0.63-3.58) 0.49 
Stage (III/IV vs I/II) 1.73 (1.06-2.83) 0.03 
 
 
Table 1. Correlation of SphK1 expression with the clinico-pathological 
parameters for the combined cohort of Singapore and Australia cases. 
The IHC data was analyzed corresponding to the combined cohort of 
Singapore and Australia colorectal cancer patients’ clinical information to 
look at the association of SphK1 with various clinico-pathological parameters. 
P-value tests for association between SphK1 expression and the various 
clinical features using Chi Square test. High SphK1 levels were found to be 














(Total n = 303) 
n 
Low SphK1 
(n = 109) 
High SphK1 
(n = 194) 
Tumour size    
< 5cm 178 (58.7%) 77 (72.5%) 101 (52.1%) 
≥ 5cm 115 (41.3%) 30 (27.5%) 85 (47.9%) 
    
Lymphatic invasion    
No 273 (90.1%) 97 (89.0%) 176 (90.7%) 
Yes 30 (9.9%) 12 (11.0%) 18 (9.3%) 
    
Perineural invasion    
No 285 (94.1%) 100 (17.4%) 185 (95.4%) 
Yes 18 (5.9%) 9 (82.6%) 9 (4.6%) 
    
Vascular invasion    
No 269 (88.8%) 93 (85.3%) 176 (90.7%) 






Test of Significance 
(p-value) 
Tumour size (≥5cm vs <5cm) 1.96 (1.19-3.25) 0.01 
Lymphatic invasion (yes vs no) 0.83 (0.38-1.79) 0.63 
Perineural invasion (yes vs no) 0.54 (0.21-1.41) 0.20 
Vascular invasion (yes vs no) 0.59 (0.29-1.22) 0.15 
 
 
Table 2. Correlation of SphK1 expression with additional clinico-
pathological parameters available for the Singapore cohort. 
The IHC data was analyzed corresponding to the additional Singapore 
colorectal cancer patients’ clinical information to look at the association of 
SphK1 with other clinico-pathological parameters. P-value tests for 
association between SphK1 expression and the various clinical features using 
Chi Square test. High SphK1 levels were found to be significantly correlated 









3.2 SphK1 protein expression and activity in the colorectal cancer cell 
lines. 
The expression of SphK1 and SphK activity were investigated in a 
panel of colon cancer cell lines which included HCT116, RKO, SW480 and 
SW620 (Fig.4). The characteristics of each colorectal cancer cell line are as 
summarized (Table 3). SphK1 expression was detected in all cell lines, with 
the highest expression in RKO cells, consistent with previous reports (Nemoto 
et al, 2009). Serum (10% FBS) stimulated the SphK activity in these cell lines, 
with peak activities ranging from 26 to 64% above the basal non-serum 
stimulated levels at 5 minutes after treatment (Fig.5). Importantly, the serum-
induced peaks in SphK activity were significantly attenuated with the pre-
treatment of the SphK1-specific inhibitor 5c (Wong et al, 2009), indicating 
that SphK1 is a major determinant of serum-induced SphK activity in these 



























Cell Line Derived from Gene mutations present 
HCT116 Colorectal carcinoma P16/CDKN2 (Inactivating Mutation) – Tumor 
suppressor that regulates cell cycle 
β-catenin/CTNNB (Activating Mutation) – 
Oncogene associated with colorectal cancer 
KRAS (Activating Mutation) – Oncogene 
MLH1/HNPCC (Activating Mutation) – Gene 
commonly associated with hereditary 
nonpolyposis colorectal cancer 
PIK3CA (Activating Mutation) – Catalytic 
subunit of PI3K 
RKO Poorly differentiated 
colon carcinoma 
BRAF (Activating Mutation) – Serine/Threonin 
protein kinase, Oncogene 
NF1 (Inactivating Mutation) – Associated with 
tumor disorder 
PIK3CA (Activating Mutation) – Catalytic 
subunit of PI3K 
SW480 Dukes’ type B, 
Colorectal 
adenocarcinoma 
β-catenin/CTNNB (Activating Mutation) – 
Oncogene associated with colorectal cancer 
EGFR (Activating Mutation) – Growth factor 
receptor 
FBXW7 (Inactivating Mutation) – Encodes F-
box proteins that constitutes the ubiquitin 
protein ligase complex, tumor suppressor 
SW620 Dukes’ type C, 
Colorectal 
adenocarcinoma, 
Derived from lymph 
nodes 
APC (Inactivating Mutation) – Tumor 
suppressor, mutation contributes to colorectal 
cancer 
KRAS (Activating Mutation) – Oncogene 
MAP2K4 (Activating Mutation) – Direct 
activator of MAPKs 
SMAD4 (Activating Mutation) – Transcription 
factor 




Table 3. Characteristics of each colorectal cancer cell line screened. 
Each colorectal cancer cell line contains specific mutations and this attributes 
to their responses to drug treatment. CDKN2, Cyclin-dependent kinase 
inhibitor 2A; KRAS, Kirsten rat sarcoma viral oncogene homolog; NF1, 
Neurofirbomatosis type I; EGFR, Epidermal growth factor receptor; APC, 
Adenomatous polyposis coli. List of mutations obtained from 
http://www.sanger.ac.uk/perl/genetics/CGP/core_line_viewer?action=cell_line
s  



















Fig.4. SphK1 is highly expressed in the colorectal cancer cell lines 
SphK1 protein levels in HCT116, RKO, SW480, and SW620 cells were 
measured by western blot with antibodies against SphK1. GAPDH was used 
as a loading control. SphK1 is expressed in all 4 colorectal cancer cell lines, 




















Fig.5. Serum-induced SphK activity in the colorectal cell lines is inhibited 
by the SphK1-specific inhibitor, 5c 
Whole cell lysates were prepared respectively from HCT116 (squares), RKO 
(triangles), SW480 (circles) and SW620 (diamonds) cells pretreated with 
10μM 5c and stimulated with 10% FBS for up to 30 minutes. Control cells 
were treated with 0.1% DMSO instead of 5c (vehicle control). Equal amounts 
of protein lysates were measured for SphK activity using the Fluorometric 
SphK Assay. Treatment with the SphK1-specific inhibitor 5c reduces the 
SphK activity in all colorectal cancer cell lines tested. Results are the average 
of 3 independent experiments each. * p-value between 0 min and FBS trigger 
< 0.05; # p-value between FBS trigger (solid lines) and inhibitors (dotted 









3.3 Inhibition of SphK1 impairs cell survival. 
To further dissect how SphK1 regulates cell survival, the potential 
involvement of SphK1 in regulating cell cycle progression of cancer cells is 
investigated. Cell cycle is a process that allows cells to replicate and grow 
(Lapenna & Giordano, 2009). Cell cycle is divided into 4 main events, the G0 
phase, G1 phase, S phase and G2/M phase. Cells in the G0 phase have exited 
the cell cycle process and are not replicating. The G1 phase is termed as the 
growth phase, where the cells are synthesizing various enzymes required for 
the S phase. In the S phase, DNA synthesis occurs and cells replicate. Lastly, 
in the G2/M phase, cells undergo mitosis and separate their chromosomes into 
2 identical sets in 2 nuclei, giving rise to new daughter cells. We carried out 
cell cycle analysis using propidium iodide (PI) staining of fixed cells, which 
enables the percentages of cells in the respective phases (G1, S and G2/M) to 
be detected. Importantly, it also records the percentage of cells in the sub-G1 
phase, which reflects the proportion of dying/dead cells with fragmented 
DNA.  
Cell cycle analysis was performed on HCT116, RKO, SW480 and 
SW620 cells treated with increasing doses of 5c (10-100μM) for 24 hours. 
With the blockade of SphK1 activity, we observed significant increases in the 
sub-G1 population, indicating nuclear fragmentation and cell death, with up to 
77.5% of cells in sub-G1 using 100µM 5c (Fig.6). An example of the 
respective histograms is demonstrated in Figure 7. The percentage of cell 
death is the highest in the RKO and SW620 cells treated with 100μM of 5c, 
and this correlates to the high SphK1 protein expression in the RKO and 
SW620 cell lines respectively. Therefore, SphK1 is a pro-survival protein and 





































Fig.6. Inhibition of SphK1 activity using 5c induces colorectal cancer cell 
death  
HCT116, RKO, SW480 and SW620 cells were treated with 10-100μM of 5c 
for 24 hours in 10% FBS, then stained with PI and subjected to cell cycle 
analysis. 0.1% DMSO was added as vehicle control. There were dose-
dependent increases in the sub-G1 phases on treatment with 5c, indicating 
increased cell death in all colorectal cancer cell lines tested. Results are 













Fig.7. Inhibition of SphK1 activity using 5c induces RKO  cell death  
RKO cells were treated with 10-100μM of 5c for 24 hours in 10% FBS, then 
stained with PI and subjected to cell cycle analysis. 0.1% DMSO was added as 
vehicle control. M1 represents population of cells in sub-G1 phase; M2 
represents population of cells in G1 phase; M3 represents population of cells 
in S phase; M4 represents population of cells in G2/M phase. There were 
dose-dependent increases in the sub-G1 phases on treatment with 5c, 
indicating increased cell death in all colorectal cancer cell lines tested. 










SphK1 is up-regulated in various cancer models, including colorectal 
cancer (Kawamori et al, 2006; Kohno et al, 2006). A previous study has found 
that SphK1 expression was higher in tumors compared to normal mucosa, as 
well as in malignant adenocarcinomas compared to adenomas (Kawamori et 
al, 2006). However, in this study, the cohort size was small (n=61). In 
addition, there were no correlations made to clinico-pathological parameters 
such as survival length of cancer patients. 
In our preliminary study, we had a total of 732 colorectal tumor cases 
with 685 matched normals. The combined cohort consists of patients treated at 
the National University Health System in Singapore and patients treated at the 
St John of God HealthCare in Western Australia. In line with the previous 
study (Kawamori et al, 2006), we found that there is a significantly higher 
SphK1 expression in colorectal tumor tissues compared to the normal controls. 
Importantly, further clinical analysis revealed that this high SphK1 correlates 
with increased tumor size, advanced tumor stages and poorer survival 
prognosis of the patients. Positive correlation of SphK1 expression to tumor 
size is supported by work in the Apc Min/+ mouse model of intestinal 
tumorigenesis, which exhibits a critical requirement for SphK1 in tumor cell 
proliferation and intestinal polyp growth (Kohno et al, 2006). Our findings 
implicate SphK1 in critical roles leading to colorectal tumor growth and 
metastasis. This is consistent with previous observations that higher SphK1 
levels were detected in metastastic lesions compared to primary carcinomas 
(Kawamori et al, 2006). This implies that SphK1 is strongly associated with 
the progression of colorectal cancer towards advanced stages of malignancy, 





and as such it will be important to define its precise biological role and to 
determine if it may be used as a target for novel interventions.  
The functional role of SphK1 is investigated in vitro, and we found 
that the SphK1 protein is up-regulated in all 4 colorectal cancer cell lines 
(HCT116, RKO, SW480 and SW620) tested. Serum, which is a key growth-
promoting agent, activates SphK1 in all cell lines tested. This activation of 
SphK1 can be inhibited by pretreating cells with a novel SphK1 inhibitor 
Compound 5c. Despite having lower SphK1 expression, both HCT116 and 
SW480 cells have the highest increase in SphK1 activity upon serum 
stimulation. We postulate that this may be attributed to the specific mutations 
present in each cell line and this is discussed in Chapter 6.  
 We proposed that SphK1 may be a potential prognostic biomarker to 
identify colorectal cancer patients who are at a higher risk of a malignant 
disease. A good prognostic cancer biomarker should accurately reflect the 
severity of the disease. We have shown that high SphK1 expression correlates 
with the severity of colorectal cancer - increased tumor size, advanced tumor 
stages and poorer survival prognosis. In vitro, we have also shown that the 
blockade of SphK1 activity significantly increases colorectal cancer cell death. 
Taken together, the levels of SphK1 reflect the disease progression of 
colorectal cancer and thus SphK1 has the potential to be used as a prognostic 
tool. The levels of SphK1 in colorectal cancer patients may help oncologists 










Inhibition of SphK1 induces colorectal cancer cell cytotoxicity 
 
 In chapter 3, we showed that SphK1 is up-regulated in colorectal 
cancer and it promotes colorectal cancer cell survival by driving cell cycle 
progression. SphK1 expression correlates to increased tumor size, advanced 
tumor stages and poorer survival prognosis in the colorectal cancer patients. 
Therefore, increased SphK1 activity in these colorectal cancer cells promotes 
their survival, by protecting them from cell death. SphK1 is a potential 
prognostic biomarker to identify colorectal cancer patients who are at a higher 
risk of a malignant disease. 
 Activation of SphK1 is a common mechanism employed by cancer 
cells to overcome insults by chemotherapeutic agents (Akao et al, 2006; 
Bonhoure et al, 2008; Dayon et al, 2009; Pchejetski et al, 2005). The 
inhibition of SphK1 has been shown to overcome the resistance of cancer cells 
towards anti-cancer therapies (Nava et al, 2002; Nemoto et al, 2009; 
Pchejetski et al, 2005). In colorectal cancer, a previous study demonstrated 
that the inhibition of SphK overcomes the resistance of cancer cells to 
oxaliplatin treatment (Nemoto et al, 2009). Oxaliplatin is a platinum-based 
alkylating agent that inhibits DNA synthesis and is commonly used in 
colorectal cancer therapies. However, in this study, the authors did not employ 
a SphK1-specific inhibitor (Nemoto et al, 2009). Therefore, it is not known 
which SphK isoform is responsible for overcoming oxaliplatin resistance in 
this colorectal cancer model. 





Early studies have worked with pan-SphK inhibitors such as DMS. 
Animal models have shown that mice with the knock-out of either SphK1 or 
SphK2 can still survive because the 2 isoforms can compensate for each other 
(Allende et al, 2004; Mizugishi et al, 2005). However, a double knock-out of 
SphK1 and SphK2 is embryonic lethal (Mizugishi et al, 2005). This 
demonstrates that both SphK isoforms are important for embryonic 
development. SphK1 and SphK2 have opposing cellular functions in the 
mammalian system (Maceyka et al, 2005). They have very distinct cellular 
functions because of their different subcellular localization. For example, upon 
serum starvation, SphK2 translocates from the cytosolic to the inner cell 
membranes and induces apoptosis. SphK1 remains cytosolic (Maceyka et al, 
2005). However, artificial targeting of SphK1 to the ER switches it from pro-
survival to pro-apoptotic like SphK2, emphasizing the importance of distinct 
subcellular localization of the respective SphK isoforms in determining their 
cellular functions (Maceyka et al, 2005). 
As discussed in the introduction (Section 1.3.1) and demonstrated in 
our own results (Chapter 3), SphK1 is the oncogenic isoform of SphK that 
promotes cancer cell survival. Inhibition of SphK1 induces colorectal cancer 
cell death. On the other hand, the cellular role of SphK2 is still widely 
debated. Studies have demonstrated that SphK2 can be both pro-apoptotic 
(Igarashi et al, 2003; Liu et al, 2003; Okada et al, 2005) and pro-survival (Hait 
et al, 2007; Hait et al, 2005; Sankala et al, 2007; Schnitzer et al, 2009; Weigert 
et al, 2009), depending on the cellular context and disease model. As such, if 
pan-SphK inhibitors are given to patients for anti-cancer therapy, unknown 
SphK2-specific inhibitory effects may be observed. For example, the 





inhibition of SphK2 activity may promote cancer cell survival instead of cell 
death. Unlike SphK1 which has been shown to be over-expressed in various 
cancer models, the relative levels of SphK2 in normal and cancer cells are yet 
unclear. Therefore, the inhibition of SphK2 activity may also result in the 
death of normal non-cancerous cells and this is not a desirable effect in anti-
cancer therapies. Taken together, to minimize the unknown ‘bystander’ effects 
of SphK2 inhibition, inhibitors that target only SphK1 may be better 
therapeutic options exhibiting specificity for anti-tumor effects. 
Therefore, in this chapter, we investigate the potential of SphK1 
inhibition to treat colorectal cancer. Employing the use of a novel inhibitor of 
SphK1 - Compound 5c (5c), we investigated the specific inhibition of SphK1 
and the effects on colorectal cancer cell survival. 5c is generated by our group 
(Wong et al, 2009) and has been validated to have better inhibitory efficacy 
















4.1 Inhibition of SphK1 activity with 5c induces a dose-dependent 
cytotoxicity in colorectal cancer 
The contribution of SphK1 to colorectal cancer cell survival was 
investigated by ascertaining cell viability after treatment of cell lines 
(HCT116, RKO, SW480 and SW620) with 10-100µM 5c for 48 hours, using 
the MTT assay. MTT assay is a standard colorimetric assay used to measure 
cell viability. The yellow MTT chemical is reduced to purple formazan only in 
the presence of active mitochondrial reductase enzymes. Therefore, the 
formation of purple formazan can be directly correlated to the number of 
living cells in the sample. We found that 10-100μM 5c induces a dose-
dependent reduction in cell viability and 100μM 5c compromised cell viability 
by up to 70% (Fig. 8). This demonstrates the crucial requirement for SphK1 
activity in maintaining colorectal cancer cell survival, as well the cytotoxic 
potential of 5c in killing these cancer cells. 
Interestingly, the SW480 cells exhibit the most sensitivity to 5c-
induced cytotoxicity. We postulate that this is because the SW480 cell line has 
the least mutations that confer resistance to drug treatments (Table 3). This is 
in comparison to the other cell lines HCT116, RKO and SW620, which have 
activating mutations such as KRAS and PIK3CA (Table 3) that contributes to 
drug resistance. In addition, SW480 cells have high SphK1 activity upon 
serum stimulation. Thus, this may result in SW480 cells being more sensitive 












Fig.8. Inhibition of SphK1 using 5c induces a dose-dependent cytotoxicity 
in the colorectal cancer cell lines 
HCT116 (blue line), RKO (red line), SW480 (green line), and SW620 (yellow 
line) cells were treated with 10-100μM of 5c for 48 hours in 10% FBS, and 
then subjected to MTT assay. All readings were compared to control cells that 
are not subjected to drug treatment (cell viability taken as 100% at ‘0’ drug 
concentration). Each point was measured in triplicate and data are expressed 
as mean +/- SD. Control cells were treated with 0.1% DMSO instead of 5c 
(vehicle control). Results are expressed as a percentage of live cells relative to 
the control cells. Treatment with 5c induces cytotoxicity in the colorectal 
cancer cells. Results are representative of 3 independent experiments each. * 










4.2 Inhibition of SphK1 activity with 5c induces apoptosis in colorectal 
cancer 
We have shown that the blockade of SphK1 activity using 5c induces 
cell death of colorectal cancer cells (Chapter 3, Fig.6). Correspondingly, 
increasing doses of 5c reduces colorectal cancer cell viability (Fig.8). Using 
Annexin V assay, we investigated if the cell death induced by 5c is a result of 
enhanced apoptosis. 
Apoptosis is a programmed cell death, characterized by blebbing, loss 
of cell membrane asymmetry and attachment, cell shrinkage, DNA 
fragmentation and chromatin condensation (Elmore, 2007). Early apoptosis 
involves the translocation of phosphatidylserine (PS) from the inner leaflet to 
the outer leaflet of the plasma membrane. Exogenous Annexin V dye added to 
these cells will bind to these exposed PS with high affinity for measurement 
(Elmore, 2007).  
Annexin V staining of cells (HCT116, RKO, SW480 and SW620) 
treated with 25-100µM 5c for 24-48 hours confirmed that 5c enhances 
apoptosis of colorectal cancer cells (Fig.9), with pronounced apoptosis 
(76.1%-98.6%) observed after 48 hours treatment with 100µM 5c in the cell 
lines (Fig. 9B). The sensitivity of colorectal cancer cells to SphK1 inhibitors 
such as 5c is consistent with previous work demonstrating that SphK1 















Fig.9. Inhibition of SphK1 using 5c induces apoptosis in colorectal cancer 
cells 
HCT116 (blue bars), RKO (red bars), SW480 (green bars) and SW620 (yellow 
bars) cells were treated with 25-100μM of 5c for 24 hours (A) and 48 hours  
(B) in 10% FBS, then stained with Annexin V and the surface expression of 
phosphatidyl serine was determined using flow cytometry. Control cells were 
treated with 0.1% DMSO instead of 5c (vehicle control). Treatment with 5c 
induces apoptosis in the colorectal cancer cells. Results are representative of 3 
independent experiments each. * p-value between 10% FBS and increasing 
doses of 5c < 0.05 





4.3 Inhibition of SphK1 activity with 5c improves the sensitivity of 
colorectal cancer cells to 5-Fluorouracil  
5-Fluorouracil (5-FU) is widely used in many cancers, including 
colorectal cancer. 5-FU-based chemotherapy improves the survival chances of 
patients with resected stage III colorectal cancer (1995). However, the 
response rates of 5-FU-based chemotherapy as a first-line treatment for 
advanced colorectal cancer are only 10-15% (Johnston & Kaye, 2001). We 
tested the effectiveness of combining 5-FU with 5c to induce cytotoxicity in 
the HCT116, RKO, SW480 and SW620 cell lines. Cell viability studies using 
the MTT assay showed that 1-50μM 5-FU used as a single agent compromises 
the viability of cells, with up to 60-70% reduction in viability at 50µM 5-FU 
(Fig.10).   
To determine the effectiveness of adding 5c to 5-FU-based treatment in 
vitro, 25µM 5c was combined with increasing doses of 5-FU. From the cell 
cycle analysis results (Fig.6), we found that 25µM 5c is the minimum 
concentration that significantly increases the population of cells in sub-G1 
phase, representing cell death. The combination of 5-FU with 25µM 5c 
significantly enhances the cytotoxicity of 5-FU, with a further reduction in 
viability by up to 90%, indicating that Sphk1 inhibition sensitizes colorectal 
cancer cells to 5-FU (Fig.11).  
We also investigated the effectiveness of adding 5-FU to 5c-based 
treatment of colorectal cancer cells by combining 10μM and 25µM 5-FU with 
increasing doses of 5c (Fig.12). We found that the cytotoxicity of 5c is most 
enhanced by combination with 25µM 5-FU, with up to 90% reduction in 
viability of the cell lines when 100µM 5c is combined with 5-FU (Fig.12). 





These data suggest that the addition of SphK1 inhibitors to current 
chemotherapeutic therapies for colorectal cancer is likely to augment clinical 
responses by sensitizing tumor cells that are otherwise poorly-responsive to 





















































Fig.10. 5-FU induces cytotoxicity in the colorectal cancer cell lines  
HCT116 (blue line), RKO (red line), SW480 (green line) and SW620 (yellow 
line) cells were treated with 1-50μM of 5-FU, for 48 hours. All readings were 
compared to control cells that are not subjected to drug treatment (cell 
viability taken as 100% at ‘0’ drug concentration). All samples were then 
subjected to MTT assay. Each point was measured in triplicate and data are 
expressed as mean +/- SD. Control cells were treated with 0.1% DMSO 
instead of 5-FU (vehicle control). Results are expressed as a percentage of live 
cells relative to the control cells. Treatment with 5-FU induces cytotoxicity in 
the colorectal cancer cells. Results are representative of 3 independent 





















Fig.11. Combination of 5c and 5-FU improves the potency of 5-FU in the 
colorectal cancer cell lines 
HCT116 (blue line), RKO (red line), SW480 (green line) and SW620 (yellow 
line) cells were treated with 25μM of 5c, together with the indicated doses of 
5FU for 48 hours. All readings were compared to control cells that are not 
subjected to drug treatment (cell viability taken as 100% at ‘0’ drug 
concentration). All samples were then subjected to MTT assay. Each point 
was measured in triplicate and data are expressed as mean +/- SD. Control 
cells were treated with DMSO instead of 5-FU/5c (vehicle control). Results 
are expressed as a percentage of live cells relative to the control cells. 
Addition of 25μM of 5c enhances the cytotoxicity induced by increasing doses 
of 5-FU. Results are representative of 3 independent experiments each. * p-
value between 0µm and increasing doses of 5-FU < 0.05; # p-value between 5-















Fig.12. Combination of 5-FU and 5c improves the potency of 5c in the colorectal 
cancer cell lines 
HCT116 (blue line), RKO (red line), SW480 (green line) and SW620 (yellow line) 
cells were treated with 10μM and 25μM of 5FU, together with increasing doses of 5c 
for 48 hours. All readings were compared to control cells that are not subjected to 
drug treatment (cell viability taken as 100% at ‘0’ drug concentration). All samples 
were then subjected to MTT assay. Each point was measured in triplicate and data are 
expressed as mean +/- SD. Control cells were treated with DMSO instead of 5-FU/5c 
(vehicle control). Results are expressed as a percentage of live cells relative to the 
control cells. Addition of 25μM of 5-FU enhances the cytotoxicity induced by 
increasing doses of 5c. Results are representative of 3 independent experiments each. 
* p-value between 0µm and increasing doses of 5c < 0.05; # p-value between 5c 
treated cells (solid lines) and 5c+5-FU treated cells (dotted lines) < 0.05 
10µM 5-FU 
25µM 5-FU 






In this chapter, we investigated the inhibition of SphK1 using a novel 
SphK1-specific inhibitor Compound 5c as a therapeutic strategy to combat 
colorectal cancer cell survival in vitro. We found that the inhibition of SphK1 
activity using 5c induces a dose-dependent cytotoxicity and accelerates 
apoptotic cell death in colorectal cancer cells. There are some variations in the 
cell death results we obtained from the cell cycle analysis by PI staining and 
MTT assay respectively and we postulate that this may be attributed to the 
sensitivity of each assay. Cell cycle analysis by PI staining detects late-stage 
cell death because PI labels DNA fragments as indicated by the sub-G1 cell 
population. MTT assay, however, measures intact mitochondria with active 
reductase enzymes in living cells that may not immediately translate to cell 
death. MTT assay was used for drug combination studies as it allows the 
screening and simultaneous comparison of several different cell lines and 
concentrations of 5c at one time, as it is performed using a 96-well format. 
Our results showed that 5-FU treatment alone could only eradicate 60-
70% of the colorectal cancer cells. However, the combination treatment of 5-
FU together with the inhibition of SphK1 using 5c increases the percentage of 
cell death, up to 90%. This suggests that SphK1 activity may be elevated in 
the chemo-resistant colorectal cancer cells and this contributes to death 
resistance. This finding is supported by other studies. Previous work by 
Nemoto et al demonstrated that the sensitivity to oxaliplatin in colorectal 
cancer cells could be enhanced by combining oxaliplatin with a non-isoform 
specific SphK inhibitor, SKI (Nemoto et al, 2009). Colorectal cancer cell lines 
that were most resistant to oxaliplatin treatment had the highest SphK1 protein 





expression and activity (Nemoto et al, 2009). Therefore, combined treatment 
of oxaliplatin and SphK inhibition enhanced colorectal cancer cell death 
(Nemoto et al, 2009). In prostate cancer, specific inhibition of the SphK1/S1P 
pathway also sensitizes prostate cancer cells to docetaxel and camptothecin 
(Pchejetski et al, 2008). Furthermore, SphK1 overexpression in breast cancer 
cells induces endocrine resistance, whilst inhibition of SphK1 restores 
endocrine responsiveness (Sukocheva et al, 2006). It thus appears that the up-
regulation or sustained activity of SphK1 in cancer cells may be a critical 
‘escape’ mechanism leading to tumor cell resistance and poor response to 
chemotherapy. Inhibition of SphK1 activity blocks such ‘escape’ mechanisms 
and instead drive cancer cells towards death. Therefore, we proposed SphK1 
to be a chemotherapy sensor in colorectal cancer. This means that increased 
SphK1 expression in the tumor of colorectal cancer patients may suggest that 
the patient has a reduced chance of survival and thus may require harsher anti-
cancer treatments. 
It has been hypothesized that the ability of cancer cells to survive is 
governed by a threshold level of SphK1 activity (Pyne & Pyne, 2010). This 
means that there is a minimal level of SphK1 activity in cancer cells that allow 
them to survive and proliferate. This may partly account for why current 
chemotherapeutic regimes and strategies have failed to eradicate all cancer 
cells in patients, leading to incidents of disease relapse. The persistence of 
survival pathways, such as those mediated by SphK1, may arise because these 
pathways were not targeted. For example, SphK1 levels or SphK1 activity 
may not have been inhibited below the minimal threshold, thereby allowing 
cancer cells to continue growing. Therefore, the combination therapy of 





current chemotherapeutic drugs together with the inhibition of SphK1 might 
prove to be more effective. Addition of potent SphK1 inhibitors will help to 
significantly lower the SphK1 threshold level and thus drive cancer cells 
towards death.  
As discussed in the introduction (Section 1.1.1), the ‘double hit’ 
strategy (Mocellin et al, 2005), which refers to the potential combination of 
chemotherapeutic drugs (that induces cytotoxicity) and ‘targeted drugs’ (that 
attacks specific molecular pathways) might be a novel therapeutic strategy in 
colorectal cancer. As such, the novel combination of 5-FU (that induces 
cytotoxicity) and the inhibition of SphK1 activity using 5c (that attacks 





















Serum-induced survival signaling in colorectal cancer 
 
 In chapters 3 and 4, we have shown that SphK1 is up-regulated in 
colorectal cancer and its expression correlates with increased tumor size, late 
tumor stages and poor survival prognosis in the colorectal cancer patients. We 
demonstrated in vitro that SphK1 is activated by serum, which in turn 
promotes colorectal cancer cell survival by driving cell cycle progression. We 
validated the therapeutic potential of inhibiting SphK1 activity using a novel 
SphK1-specific inhibitor 5c. Blockade of SphK1 activity drives colorectal 
cancer cells towards apoptotic cell death. The novel combinations of 5c with 
5-FU potentiate colorectal cancer cell death, emphasizing the potential of 
inhibiting SphK1 activity as an anti-cancer strategy. 
 Despite knowing the importance of SphK1 and the potency of its 
inhibition in influencing colorectal cancer survival, the molecular mechanisms 
of SphK1 are yet unclear. SphK1 potentiates cancer progression by tilting the 
sphingolipid rheostat to favor the production of S1P, thereby activating 
important downstream pro-survival pathways (Pitson et al, 2005). In various 
disease models including cancer, SphK1 has been linked to important pro-
survival signaling players such as MAPK (Nava et al, 2002; Pitson et al, 2005; 
Shu et al, 2002), PI3K/Akt (Ader et al, 2008; Kapitonov et al, 2009; Le Scolan 
et al, 2005; Radeff-Huang et al, 2007), PKC (Johnson et al, 2002) and Bcl2 
(Limaye et al, 2005). In colorectal cancer, these pro-survival signaling 
proteins may likely be upstream/downstream players of SphK1. Therefore, in 
our subsequent studies, using a SphK1-selective inhibitor Compound 5c (5c), 





we investigated novel molecular mechanisms regulated by SphK1 to drive 
colorectal cancer cell survival (Fig.13). 
 The selectivity of 5c was validated using the human leukemia U937 
cells (Wong et al, 2009). SphK1 or SphK2 were overexpressed in these cells 
respectively, and subjected to inhibition treatment with 5c. SphK1 and SphK2 
activities were determined by measuring S1P levels, which is the lipid product 
of SphK. We found that 5c significantly inhibited S1P levels in SphK1-
overexpressing cells, but not in SphK2-overexpressing cells. This indicates 




Fig.13. SphK1 drives colorectal cancer cell survival 
Serum activates SphK1, which drives colorectal cancer cell survival. 
CRC, Colorectal Cancer. 





5.1 Pretreatment with 5c effectively inhibits the serum-induced SphK1 
translocation to the plasma membrane.  
Upon stimulation by growth factors, SphK1 is phosphorylated at the 
serine residue 225 and is immediately translocated to the plasma membrane 
where sphingosine is present. SphK1 subsequently phosphorylates sphingosine 
to S1P, thereby tilting the sphingosine rheostat towards promoting survival 
(Pitson et al, 2005). Therefore, the translocation of SphK1 to the plasma 
membrane is a critical step that promotes cancer cell survival.  
Our results showed that at basal (0 minute) when the colorectal cancer 
HCT116 cells are not stimulated, SphK1 remains in the cytosol (Fig.14). 
However, once the cells are stimulated with 10% FBS, SphK1 rapidly 
translocates to the plasma membrane after 5 minutes and the translocation is 
sustained up till 10 minutes (Fig.14). SphK1 returns to the cytosol after 30 
minutes (Fig.14). Pre-treatment of cells with 50μm 5c effectively inhibited the 
SphK1 translocation, and SphK1 remained in the cytosol throughout (Fig.14). 
This demonstrates once again that serum activates SphK1 in colorectal cancer 
(Fig.13) and that 5c is a highly potent drug that inhibits SphK1 activity. 50μM 
5c was chosen for the subsequent experiments in this chapter because from the 
MTT results (Fig.8), we found that 50µM of 5c was the minimum 
















Fig.14. 5c inhibits the serum-induced SphK1 translocation to the plasma 
membrane in HCT116 cells 
HCT116 cells were serum-starved overnight, then pretreated with 50μM 5c for 
60 minutes, and stimulated with 10% FBS for up to 30 minutes. Control cells 
were treated with 0.1% DMSO instead of 5c (vehicle control). Cells were 
fixed and probed with anti-SphK1 primary antibodies and secondary FITC 
antibodies. Treatment with 5c inhibited the membrane translocation of SphK1.  
Results are representative of 3 independent experiments each. Note that the 
experiments for Fig.14 and Fig.33 were carried out simultaneously, and 
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5.2 SphK1 activated by serum induces S1P production and release out 
of cells.  
 S1P producd upon SphK activation can either be retained 
intracellularly, or be exported out of cells to function extracellularly. 
Extracellular S1P acts as a first signaling messenger by binding to specific 
GPCRs labeled as S1P1-5 and re-entering cells in an autocrine or paracrine 
manner (Spiegel et al, 1998). Intracellular S1P that remains in the cytosol acts 
as a second signaling messenger upon the addition of stimulants such as serum 
and PDGF (Olivera & Spiegel, 1993; Spiegel & Milstien, 2003). 
 We showed that 10% FBS induces the release of S1P from HCT116 
cells (Fig.15). Pre-treatment of cells with 50μm 5c inhibited this release of 
S1P (Fig.15). Our results suggest that SphK1 activated by serum produces S1P 
in the colorectal cancer cells, which can act intracellularly and can also be 





















Fig.15. Inhibition of SphK1 using 5c inhibits S1P release from HCT116 cells 
HCT116 cells were serum-starved overnight, then pretreated with 50μM 5c for 60 
minutes, and stimulated with 10% FBS for up to 180 minutes. Control cells were 
treated with 0.1% DMSO instead of 5c (vehicle control). Supernatant of cells were 
collected and S1P levels were measured. A, Raw readings of S1P release in one 
representative experiment. B, Normalised fold change over control cells (Average of 
3 independent experiments). Treatment with 5c inhibited the release of S1P.  * p-
value between 0 min (black bars) and FBS trigger (black bars) < 0.05; # p-value 
between FBS trigger (black bars) and inhibitors (green bars) < 0.05. 
Levels of S1P released (Representative set) 
Normalised levels of S1P released  
(Average of 3 sets) 








Fig.16. SphK1 signals through S1P to promote HCT116 cell survival 
Serum activates SphK1, which produces S1P. From literature, it is known that 
S1P can either function intracellularly or be transported out of cells to function 
extracellularly. Inhibition of SphK1 activity using 5c inhibits both SphK1 
translocation and S1P release. Extracellular S1P binds to cell surface S1PRs to 
enter cells, and drugs such as pertussis toxin can block these S1PRs. 











5.3 PI3K regulates SphK1 activity, which in turn regulates Akt 
phosphorylation.  
 The PI3K pathway plays an important role in cancer cell growth and 
survival. Akt is the major effector of PI3K. Activated Akt promotes cell 
survival by down-regulating apoptosis, promoting the cell cycle progression, 
regulating nutrient uptake and metabolism, and cross-activating other survival 
pathways (Carnero, 2010). The link between SphK1 and Akt has been 
established in several models of cell proliferation (Ader et al, 2008; Dayon et 
al, 2009; Francy et al, 2007; Kapitonov et al, 2009; Le Scolan et al, 2005; 
Nemoto et al, 2009; Radeff-Huang et al, 2007). In colorectal cancer, there are 
only preliminary data linking SphK1 to Akt in the oxaliplatin-resistant cancer 
cells. Oxaliplatin is a platinum-based alkylating agent that interferes with 
DNA synthesis. Colorectal cancer cells treated with oxaliplatin activates 
SphK1 and Akt (Nemoto et al, 2009), and potentially confers resistance to 
oxaliplatin. The use of a non-selective SphK inhibitor (SKI) down-regulated 
the levels of phosphorylated Akt induced by oxaliplatin and overcame the 
resistance of cancer cells to oxaliplatin treatment (Nemoto et al, 2009). 
Therefore, the PI3K/Akt pathway is a potential mechanism regulated by 
SphK1 to promote colorectal cancer survival, particularly in drug resistant 
cells. However, the inhibitor used in the study was non-selective for SphK1 
(Nemoto et al, 2009). Thus, it is still unclear how SphK1 is linked to the 
PI3K/Akt pro-survival pathway in colorectal cancer. In our subsequent work, 
we set out to establish the relationship between SphK1 and Akt. 
 Our results showed that in HCT116 cells, inhibition of PI3K activity 
using 5µm of LY294002 (LY29) inhibits the 10% FBS-induced SphK1 





activity (Fig.17). As LY29 is a PI3K-specific inhibitor, this indicates that 
PI3K regulates SphK1 activity triggered by 10% FBS. We observed that 10% 
FBS induces phosphorylation of Akt at the Thr308 and Ser473 residues 
(Fig.18), indicating the full activation of Akt. The phosphorylation of Akt 
peaks at 30 minutes and is sustained up till 300 minutes. Pre-treatment of cells 
with 50μM of 5c significantly inhibited the phosphorylation of Akt at both the 
Thr308 and Ser473 residues, from 30 minutes up till 300 minutes (Fig.18). 
This indicates that SphK1 regulates the serum-induced Akt activity.  
Exogenous S1P was then added to cells pre-treated with 5c, in an 
attempt to reverse the inhibitory effects of 5c on Akt phosphorylation. 
Exogenous S1P either binds to S1P receptors on cells to function as an 
extracellular first messenger, or it enters cells directly to function 
intracellularly (Van Brocklyn et al, 1998). Upon stimulation with 10% FBS, 
1µm of exogenous S1P overcame the inhibitory effect of 5c on the 
phosphorylation of Akt at 30-60 minutes (Fig.19). However, exogenous S1P 
was not effective in increasing Akt phosphorylation from 180-300 minutes, as 
Akt activation remained inhibited by 5c (Fig.19). We hypothesize that there 
may be unknown S1P-independent mechanisms induced by SphK1 that 
regulates the long-term activity of Akt.  
In summary, when we stimulate colorectal cancer cells with serum, 
activated PI3K activates SphK1 which phosphorylates sphingosine to S1P to 
further regulate Akt activation. Whilst the earlier Akt activation is dependent 
on S1P, SphK1 may also exert S1P-independent effects on long-term Akt 
activation. 
 









Fig.17. PI3K regulates SphK1 activity in HCT116 cells 
HCT116 cells were serum-starved overnight, then pretreated with 5μM LY29 
(a PI3K inhibitor) for 60 minutes, and stimulated with 10% FBS for up to 30 
minutes. Control cells were treated with 0.1% DMSO instead of LY29 
(vehicle control). Equal amounts of protein lysates were used for SphK 
activity using the Fluorometric SphK Assay. Inhibition of PI3K by LY29 
resulted in a reduction in SphK activity. Results are representative of 3 
independent experiments each. * p-value between 0 min (closed green 
squares) and FBS trigger (closed green squares) < 0.05; # p-value between 















Fig.18. SphK1 regulates Akt phosphorylation in HCT116 cells 
HCT116 cells were serum-starved overnight, then pretreated with 50μM 5c for 
60 minutes, and stimulated with 10% FBS for up to 300 minutes. Control cells 
were treated with 0.1% DMSO instead of 5c (vehicle control). Equal amounts 
of protein lysates were immunoblotted with anti-phospho-AktSer473, Thr308 or 
anti-total-Akt antibodies. Inhibition of SphK1 with 5c inhibited the 
phosphorylation of Akt stimulated by serum. Results are representative of 3 















Fig.19. SphK1 signals through S1P to regulate Akt phosphorylation in 
HCT116 cells 
HCT116 cells were serum-starved overnight, then pretreated with 50μM 5c for 
60 minutes, and stimulated with 10% FBS and 1μM S1P for up to 300 
minutes. Control cells were treated with 0.1% DMSO instead of 5c (vehicle 
control). Equal amounts of protein lysates were immunoblotted with anti-
phospho-AktSer473 or anti-total-Akt antibodies. The addition of exogenous S1P 
overcomes the inhibitory effect of 5c on Akt phosphorylation at 30-60 
minutes, but is less effective from 180-300 minutes. Results are representative 










5.4 Both the intracellular and extracellular S1P induces Akt 
phosphorylation.  
Serum-activated SphK1 phosphorylates sphingosine to S1P which can 
be released out of cells (Fig.15). Exogenous S1P overcomes the inhibitory 
effect of 5c on Akt phosphorylation, suggesting that S1P mediates the SphK1-
regulated Akt activation (Fig.19). Exogenous S1P added to cells can either 
mimic an intracellular second messenger or bind to S1P receptors as a first 
messenger (Van Brocklyn et al, 1998). Thus, we investigated further to find 
out the relative contributions of intracellular and extracellular S1P on SphK1-
regulated Akt activation. We used pertussis toxin (PTX) to inhibit the S1P 
receptors that bind to downstream PTX-sensitive Gi proteins (Goodemote et 
al, 1995). It has been shown previously that treatment with PTX inhibits the 
pro-survival effects (DNA synthesis) induced by exogenous S1P (Goodemote 
et al, 1995). Therefore, PTX partially blocks the effects of exogenous S1P as a 
first messenger. This then allows us to distinguish whether exogenous S1P 
functions as a first or second messenger in the serum-induced colorectal 
cancer cell survival. 
Our result showed that 1µm of exogenous S1P induces Akt 
phosphorylation, up till 300 minutes (Fig.20). With the addition of 100ng/ml 
of PTX, this phosphorylation was partially inhibited, indicating that binding of 
S1P to its extracellular S1P receptors is partly responsible for Akt activation 
(Fig.20). Our data suggests that both the intracellular and extracellular S1P are 
involved in the activation of Akt (Fig. 21).  
 
 









Fig.20. Intracellular & extracellular S1P induce Akt phosphorylation in 
HCT116 cells 
HCT116 cells were serum-starved overnight, then pretreated with 100ng/ml 
PTX for 120 minutes, and stimulated with 1μM S1P for up to 300 minutes. 
Equal amounts of protein lysates were immunoblotted with anti-phospho-
AktSer473 or anti-total-Akt antibodies. Treatment with PTX partially inhibited 
the Akt phosphorylation stimulated by exogenous S1P. Results are 















Fig.21. Serum activates a PI3K-SphK1-S1P-Akt pathway to promote 
HCT116 cell survival 
Upon serum stimulation, PI3K activates SphK1. Akt which is an important 
downstream pro-survival protein, is in turn activated by SphK1 and S1P that 
can either function intracellularly and extracellularly. 











5.5 Serum activates PKCδ and PKCζ. 
PKC is a key signaling protein in many survival pathways. The PKC 
family consists of 11 isoforms with very diverse biological functions. They are 
classified into 3 families – classical PKCs (PKCα,βI,βII,γ); novel PKCs 
(PKCδ,ε,η,θ,μ); atypical PKCs (PKCζ,ι/λ). Although each PKC family have 
slightly different activation mechanisms (Chou et al, 1998; Hirai & Chida, 
2003; Shen, 2003; Zhou et al, 1994), all known PKC isoforms are first 
translocated from the cytosol to the plasma membrane before they are 
activated. Therefore, the translocation of specific PKC isoforms in cancer cells 
is indicative of its activation (Wang et al, 2005; Zeidan & Hannun, 2007).   
In colorectal cancer, PKCβII and PKCι are two well-studied PKC 
isoforms that were found to promote colorectal tumor progression. Lesser 
information is available about the roles of other PKC isoforms in colorectal 
cancer. Nonetheless, as discussed in the introduction chapter (Section 1.7.1), 
PKC isoforms such as PKCδ, PKCε and PKCζ may also be key players that 
influence colorectal cancer survival (Cerda et al, 2001; Mischak et al, 1993; 
Mustafi et al, 2006). PKCδ was shown to be pro-apoptotic in colorectal cancer 
(Cerda et al, 2001), but pro-survival in breast cancer (Lønne et al, 2009). 
PKCε opposes the effects of PKCδ in fibroblasts and promotes tumor 
formation (Mischak et al, 1993). PKCζ was shown to be pro-apoptotic in both 
colorectal and ovarian cancers (Mustafi et al, 2006; Nazarenko et al, 2010). 
Therefore, we hypothesize that PKCδ, PKCε and PKCζ are important 
signaling proteins in colorectal cancer cells and they may potentially interact 
with SphK1 and Akt to influence colorectal cancer cell survival.  





We found that serum activates PKCδ and PKCζ, but did not activate 
PKCε (Fig.22). At basal conditions (0 minute), all 3 PKC isoforms remained 
cytosolic. Upon the stimulation of 10% FBS, PKCδ translocates to the plasma 
membrane at 10 minutes, while PKCζ translocates to the plasma membrane at 
5 minutes (Fig.22). By 30 minutes, both PKCδ and PKCζ have returned to the 
cytosol (Fig.22). PKCε remained cytosolic throughout the 30 minutes 
(Fig.22). Our results suggest that serum activates specific PKC isoforms in 
colorectal cancer cells, in particular the PKCδ and PKCζ isoforms. 
To investigate the potential roles of PKCδ and PKCζ in colorectal 
cancer cell survival, we first employed the use of Bisindolylmaleimide I (Bis 
I). Bis I is a dose-dependent inhibitor of PKC (Martiny-Baron et al, 1993; 
Toullec et al, 1991). Bis I inhibits classical PKCs (cPKCs) at very low doses 
(0.01μm), inhibits novel PKCs (nPKCs) at mod erate doses (0 .1 μm) and 
inhibits aytpical PKCs (aPKCs) at very high doses (6-10μm). As shown in our 
results, 0.1μm of Bis I inhibits the serum-induced translocation of the novel 
isoform PKCδ (Fig.23), but not that of the atypical isoform PKCζ (Fig.23). 
With the pre-treatment of 0.1μm of Bis I, PKCδ remained cytosolic even with 
serum stimulation (Fig.23). Therefore, 0 .1 μm of Bis I is a suitable dose to 
block PKCδ activity and allow us to study the effect of such blockade. 
To further validate the role of PKCδ in colorectal cancer, PKCδ was 
subsequently knocked-down in HCT116 cells by siRNA (Fig.24). 
Interestingly, this knock-down of PKCδ reduced the HCT116 cell viability by 
25% (Fig.25),` indicating that PKCδ is a p ro-survival protein in colorectal 
cancer (Fig.26). 
 










Fig.22. Serum induces PKCδ and PKCζ translocation to the plasma 
membrane, but not PKCε, in HCT116 cells 
HCT116 cells were serum-starved overnight, then stimulated with 10% FBS 
for up to 30 minutes. Cells were fixed and probed with anti-PKCδ/ε/ζ primary 
antibodies and secondary FITC antibodies. Serum stimulated the membrane 
translocation of PKCδ and PKCζ, but not PKCε. Results are representative of 
3 independent experiments each. Note that the experiments for Fig.21, Fig.22 
and Fig.26 were carried out simultaneously, and compared with the same 
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Fig.23. 0.1μM of Bis I inhibits PKCδ translocation, but not PKCζ to the 
plasma membrane in HCT116 cells 
HCT116 cells were serum-starved overnight, then pretreated with 0.1μM Bis I 
for 60 minutes, and stimulated with 10% FBS for up to 30 minutes. Control 
cells were treated with 0.1% DMSO instead of Bis I (vehicle control). Cells 
were fixed and probed with anti-PKCδ/ζ primary antibodies and secondary 
FITC antibodies. Treatment with 0.1μM Bis I inhibited the membrane 
translocation of the novel isoform PKCδ, but not that of the atypical isoform 
PKCζ.  Results are representative of 3 independent experiments each.  
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Fig.24. Knock-down of PKCδ in HCT116 cells 
HCT116 cells were transfected with 10nM of either PKCδ siRNA or negative 
control siRNA. Lane 1 represents untransfected wildtype HCT116 cells; Lane 
2 represents HCT116 cells transfected with PKCδ siRNA; Lane 3 represents 
HCT116 cells transfected with the negative control siRNA. Equal amounts of 
protein lysates were immunoblotted with anti- PKCδ and anti-SphK1 
antibodies respectively GAPDH was used as a loading control. Transfection of 
PKCδ siRNA in HCT116 cells knocked down 90% of PKCδ protein 






























Fig.25. Knock-down of PKCδ down-regulates HCT116 cell viability 
HCT116 cells were transfected with 10nM of either PKCδ siRNA or negative 
control siRNA, and then subjected to MTT assay. Each point was measured in 
triplicate and data are expressed as mean +/- SD. Results are expressed as a 
percentage of live cells relative to the negative control. Knock-down of the 
PKCδ protein down-regulated HCT116 cell viability. Results are 









































Fig.26. Serum stimulates PKCδ and PKCζ activities in HCT116 cells 
Serum activates both PKCδ and PKCζ in HCT116 cells. PKCδ is a pro-
survival protein because the knock-down of PKCδ reduces HCT116 cell 












5.6 SphK1 regulates PKCδ activity. 
Earlier studies have shown that S1P promotes PKC activity by 
elevating DAG levels (Spiegel et al, 1998). DAG is important for the 
activation of classical and novel PKCs. This suggests that SphK1, that drives 
the production of S1P, may be regulating PKC activity in colorectal cancer. 
However, the PKC isoforms regulated by SphK1/S1P are yet unknown. We 
hypothesize that SphK1 may regulate specific PKC isoforms to promote 
colorectal cancer cell survival. As demonstrated in our results, the blockade of 
SphK1 activity in HCT116 cells with 50µm of 5c inhibits PKCδ translocation 
to the plasma membrane (Fig.27), thereby inhibiting the activation of PKCδ. 
This suggests that SphK1 regulates PKCδ activity in colorectal cancer 
(Fig.29).  
On the other hand, blockade of SphK1 with 50µm of 5c did not inhibit 
the translocation of PKCζ (Fig.27). Instead, pretreatment of cells with a very 
high dose of 5c (100µm) further induced the translocation of PKCζ (at 0 
minute) even without serum stimulation (Fig.28).  We have previously showed 
that 100µm of 5c induces up to 90% apoptotic cell death in the HCT116 cell 
line. Thus, pretreatment with 100µm of 5c may activate PKCζ to trigger 
apoptosis in HCT116 cells. In line with other studies, PKCζ has been shown to 
behave as a pro-apoptotic protein in colorectal cancer cells (149). Therefore, 
the enhancement of PKCζ activity by 5c ties in with our findings to date.  















Fig.27. SphK1 regulates PKCδ translocation to the plasma membrane in 
HCT116 cells 
HCT116 cells were serum-starved overnight, then pretreated with 50μM 5c for 
60 minutes, and stimulated with 10% FBS for up to 30 minutes. Control cells 
were treated with 0.1% DMSO instead of 5c (vehicle control). Cells were 
fixed and probed with anti-PKCδ/ζ primary antibodies and secondary FITC 
antibodies. Inhibition of SphK1 with 5c inhibited the membrane translocation 
of PKCδ, but no t that of PKCζ.  Results are representative of 3 independent 
experiments each.  
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Fig.28. High dose of 5c further enhances the basal PKCζ translocation to 
the plasma membrane in HCT116 cells 
HCT116 cells were serum-starved overnight, then pretreated with 100μM 5c 
for 60 minutes, and stimulated with 10% FBS for up to 30 minutes. Control 
cells were treated with 0.2% DMSO instead of 5c (vehicle control). Cells were 
fixed and probed with anti- PKCζ primary antibodies and secondary FITC 
antibodies. Inhibition of SphK1 with a very high dose of 5c enhanced the 
membrane translocation of PKCζ.  Results are representative of 3 independent 
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Fig.29. SphK1 regulates the serum-induced PKCδ activity in HCT116 
cells 
SphK1 activated upon serum stimulation further activates PKCδ, but not 
PKCζ. Activated PKCδ promotes HCT116 cell survival. CRC, Colorectal 












5.7 PKCδ mediates the SphK1/S1P-regulated Akt activity. 
There is evidence of interactions between PKC and PI3K/Akt 
pathways. Both PKC and Akt are substrates of phosphoinositide-dependent 
kinase-1 (PDK-1), a serine-threonine kinase. Activation of PKCs and Akt first 
require phosphorylation by PDK-1. PI3K also regulates the activation of 
PKCδ and  PKCζ v ia the regulatory domain of PDK-1 (Chou et al, 1998; Le 
Good et al, 1998). PKCζ in turn interacts and negatively regulates Akt 
(Doornbos et al, 1999; Mao et al, 2000). 
We have shown that SphK1 regulates PKCδ activity in colorectal 
cancer, thus we hypothesize that PKCδ may mediate the SphK1-regulated Akt 
activity. Our results showed that when PKCδ is knocked-down in HCT116 
cells, the serum-induced Akt phosphorylation at the serine 473 residue is 
significantly inhibited from 30 minutes till 180 minutes (Fig.30). This 
indicates that PKCδ regulates Akt activity in the colorectal cancer cells.  
In addition, S1P induces the translocation of PKCδ to the plasma 
membrane (Fig.31). This S1P-induced PKCδ translocation is inhibited upon 
the pre-treatment of cells with 100ng/ml of PTX (Fig.31). The knock-down of 
PKCδ inhibited the S1P-induced Akt phosphorylation (Fig.32). Taken 
together, we found that the SphK1/S1P pathway regulates PKCδ which in turn 
mediates Akt activity. This is a novel pathway in colorectal cancer that 














Fig.30. PKCδ regulates Akt phosphorylation in HCT116 cells 
PKCδ siRNA knocked-down HCT116 cells were serum-starved overnight, 
then stimulated with 10% FBS for up to 180 minutes. Equal amounts of 
protein lysates were immunoblotted with anti-PKCδ, anti-phospho-AktSer473 or 
anti-total-Akt antibodies. Results were compared against the negative control 
siRNA knocked-down HCT116 cells. GAPDH was used as a loading control. 
Knock-down of PKCδ inhibited Akt phosphorylation stimulated by serum. 























Fig.31. S1P regulates PKCδ translocation to the plasma membrane in 
HCT116 cells 
HCT116 cells were serum-starved overnight, then pretreated with 100ng/ml 
PTX for 120 minutes, and stimulated with 1µm S1P for up to 30 minutes. 
Cells were fixed and probed with anti- PKCδ primary antibodies and 
secondary FITC antibodies. Treatment with PTX inhibited the membrane 
translocation of PKCδ stimulated by exogenous S1P. Results are 
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Fig.32. S1P signals through PKCδ to regulate Akt phosphorylation in 
HCT116 cells 
PKCδ siRNA knocked-down HCT116 cells were serum-starved overnight, 
then stimulated with 1μM S1P for up to 180 minutes. Equal amounts of 
protein lysates were immunoblotted with anti-PKCδ, anti-phospho-AktSer473 or 
anti-total-Akt antibodies. Results were compared against the negative control 
siRNA knocked-down HCT116 cells.  GAPDH was used as a loading control. 
Knock-down of PKCδ inhibited Akt phosphorylation stimulated by exogenous 

















Fig.33. Serum activates a PI3K-SphK1-S1P-PKCδ-Akt pathway to 
promote HCT116 cell survival 
Serum activates PI3K, which activates SphK1 to produce S1P. S1P can 
function intracellularly and extracellularly to activate PKCδ, which will in turn 












5.8 PKCδ regulates SphK1 activity.  
In the above section, we have demonstrated that PKCδ acts 
downstream of SphK1 and S1P to activate Akt. The link between PKC and 
sphingolipids has been demonstrated in several studies (Chmura et al, 1997; 
Cuvillier et al, 1996; Shu et al, 2002; Spiegel et al, 1998). Majority of these 
studies found PKC to be acting upstream of SphK1/S1P. PKC mediates the 
translocation of SphK1 to the plasma membrane, thus inducing secretion of 
S1P out of cells (Johnson et al, 2002). PKC activates the SphK/S1P pathway 
to rescue cells from TNF-induced cell death (Cuvillier et al, 1996), and to 
promote VEGF-induced endothelial cell growth (Shu et al, 2002). These 
findings led us to hypothesize that PKC may also act upstream of SphK1/S1P 
in colorectal cancer. 
 In the HCT116 cells, we found that treatment with the PKC inhibitor, 
Bis I, also inhibits SphK1 activity. 0.1μm of Bis I inhibits SphK1 activity 
(Fig.34) and SphK1 translocation to the plasma membrane (Fig.34). With the 
pre-treatment of Bis I, SphK1 activity in the HCT116 cells remained at basal 
levels (Fig.34) and SphK1 protein remained cytosolic (Fig.34) even with 
serum stimulation. This inhibition of SphK1 activity was sustained even when 
a lower d ose of Bis I (0 .0 1 μm) was u sed (Fig .34). This suggests that both 
classical PKCs and novel PKCs may regulate SphK1 in colorectal cancer.  
 To further elucidate the relationship between SphK1 and PKCδ, we did 
further studies to check if PKCδ may also act upstream of SphK1. Although 
the knock-down of PKCδ in HCT116 cells did not affect the basal SphK1 
protein expression (Fig.24), it inhibits the translocation of SphK1 to the 
plasma membrane upon serum stimulation (Fig.35), thereby blocking 





subsequent SphK1 activation. Similarly, in the PKCδ knocked-down cells, 
serum could not stimulate SphK activity (Fig.35). Taken together, these results 
suggest that PKCδ regulates SphK1 in colorectal cancer.  
We have elucidated a novel feedback mechanism between SphK1 and 
PKCδ. Serum activates PI3K, which activates SphK1/S1P to further activate 
PKCδ. Activated PKCδ activates downstream Akt, and at the same time 
feedback to activate SphK1, thereby potentiating its own activation and 
























Fig.34. Classical and novel PKCs regulates SphK1 activity and membrane 
translocation in HCT116 cells 
HCT116 cells were serum-starved overnight, then pretreated with 0.01μM or 
0.1μM Bis I for 60 minutes, and stimulated with 10% FBS for up to 30 
minutes. Control cells were treated with 0.1% DMSO instead of Bis I (vehicle 
control). Equal amounts of protein lysates were measured for SphK activity 
using the Fluorometric SphK Assay. Cells were also fixed and probed with 
anti-SphK1 primary antibodies and secondary FITC antibodies. Treatment 
with 0.1μM Bis I inhibited the activity and membrane translocation of SphK1. 
Results are representative of 3 independent experiments each. * p-value 
between 0 min and FBS trigger < 0.05; # p-value between FBS trigger and 
inhibitors < 0.05. 
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Fig.35. PKCδ regulates SphK1 activity and membrane translocation in 
HCT116 cells 
PKCδ siRNA knocked-down HCT116 cells were serum-starved overnight, 
then stimulated with 10% FBS for up to 30 minutes. Equal amounts of protein 
lysates were measured for SphK activity using the Fluorometric SphK Assay. 
Cells were also fixed and probed with anti-SphK1 primary antibodies and 
secondary FITC antibodies. Knock-down of PKCδ inhibited the activity and 
membrane translocation of SphK1. Results are representative of 3 independent 
experiments each. * p-value between 0 min and FBS trigger < 0.05; # p-value 
between FBS trigger and inhibitors < 0.05. 
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Fig.36. Serum activates a novel SphK1-PKCδ feedback mechanism to 
promote HCT116 cell survival 
Activated PKCδ upon serum stimulation feedbacks to activate SphK1. This 
potentiates its own activation, and also amplifies the entire signaling pathway 













 In this chapter, we investigated novel molecular mechanisms 
underlying how SphK1 mediates the serum-induced HCT116 colorectal cancer 
cell survival. HCT116 was selected as the model cell line in this chapter 
because it contains the KRAS mutation. The oncogene KRAS is important in 
the development of colorectal cancer and is a leading genetic factor for drug 
resistance (Lee et al, 2011). 
We established a novel link between SphK1 and the pro-survival 
proteins Akt and PKCδ. Several studies have suggested the link between 
SphK1 and Akt (Ader et al, 2008; Dayon et al, 2009; Francy et al, 2007; 
Kapitonov et al, 2009; Le Scolan et al, 2005; Nemoto et al, 2009; Radeff-
Huang et al, 2007) and PKCs (Chmura et al, 1997; Cuvillier et al, 1996; Shu et 
al, 2002; Spiegel et al, 1998) respectively. However, in colorectal cancer, there 
are no clear evidence linking SphK1, PKCs and Akt. Elucidating the signaling 
relationship between these pro-survival signaling players helps in the 
understanding of how colorectal cancer cells evade anti-cancer therapies and 
be resistant to cell death.  
As illustrated in Figure 35, we found that serum (10% FBS) stimulates 
the activation of PI3K, SphK1, and specific PKC isoforms such as PKCδ and 
PKCζ in colorectal cancer cells. In response to serum, PI3K promotes the 
activation of SphK1 and the subsequent phosphorylation of sphingosine to 
S1P. S1P produced can function both intracellularly as a second messenger 
and extracellularly on S1P receptors. The activated SphK1/S1P pathway 
activates PKCδ, which in turn activates Akt.  





We also found that PKCδ and SphK1 tightly regulate each other via a 
novel feedback loop relationship. Classical PKCs and the novel isoform PKCδ 
regulate SphK1 activity. This finding is supported by Paugh et al, who 
demonstrated that PKCδ acts upstream of SphK1 in a glioblastoma model 
(Paugh et al, 2008). Therefore, SphK1 activates PKCδ, which feedback to 
activate SphK1, resulting in a signal amplification. The end-point of these 
signaling effects stimulated by serum is the activation of Akt, which promotes 
cell survival by driving the cell cycle progression. This novel SphK1-S1P-
PKCδ-Akt pro-survival signaling pathway induced by serum correlates with 
our previous findings that SphK1 drives the cell cycle progression of 
colorectal cancer cells (Chapter 3). We now understand how SphK1 promotes 
colorectal cancer cell survival.  
Previously, Cerda et al have found that PKCδ is pro-apoptotic in 
colorectal cancer (Cerda et al, 2001; Mustafi et al, 2006). Overexpression of 
PKCδ inhibited Caco-2 colorectal cancer cell growth and cell cycle 
progression, promoted cell differentiation and apoptosis. In our study, 
however, we found that serum activates PKCδ in colorectal cancer cells. 
Knock-down of PKCδ in the HCT116 cell line down-regulated the serum-
induced cell viability, emphasizing a pro-survival role for PKCδ. Our finding 
contradicts that of Cerda et al. It could arise from the different colorectal 
cancer cell lines used. In addition, Cerda et al chose to over-express PKCδ to 
study its effects. In our project, we used serum instead to activate PKCδ 
intracellularly. All these could be the influencing factors that account for the 
contradiction we observed.  





The PI3K/Akt pathway is very well-established in colorectal cancer. 
The frequent gain-of-function mutations in the catalytic subunit of PI3K 
(PIK3CA) increased Akt activation, leading to increased tumor growth rates 
and metastasis (Samuels et al, 2004). This is evident in clinical studies, 
whereby Akt is hyperphosphorylated in metastatic colorectal cancer patients 
(Roy et al, 2002). PIK3CA mutations result in the constitutive activation of 
PI3K, which induce the lack of response to chemotherapeutic drugs such as 
cetuximab and panitumumab (Jhawer et al, 2008; Loupakis et al, 2009). 
Therefore, it is important to elucidate novel signaling pathways downstream of 
PI3K in colorectal cancer, to be targeted as therapeutic strategies to kill cancer 
cells. We have shown in this chapter that SphK1 lies downstream of PI3K. 
Activated SphK1 further activates PKCδ. The novel feedback loop between 
SphK1 and PKCδ amplifies the signaling pathway to activate Akt. This 
suggests that by inhibiting SphK1 activity, we can block these pro-survival 
signaling mechanisms that lead to Akt activation and thereby overcome the 














Discussion & Future Work 
 Colorectal cancer is the third most common cancer in the world and the 
fourth most common cause of cancer-related mortality (Ferlay et al, 2010). 
Although 5-FU has been used as a first-line treatment for advanced colorectal 
cancer and improves the survival of patients, up to 85-90% of patients still 
respond poorly (Johnston & Kaye, 2001). More recently, monoclonal 
antibodies against growth factors have been developed and tested in clinical 
trials for advanced colorectal cancer (Knijn et al, 2010). These include 
bevacizumab, an antibody against the vascular endothelial growth factor 
(VEGF), as well as cetuximab and panitumumab, antibodies against the 
epidermal growth factor (EGF) (Knijn et al, 2010). These antibodies are more 
effective when used in combination with 5-FU, compared to use as single 
agents (Knijn et al, 2010). However, a significant percentage of patients may 
not benefit from treatment with these drugs.  For example, cetuximab is 
ineffective in cancers with KRAS mutations, which are found in 
approximately 38% of colorectal cancers (Knijn et al, 2010). Drugs which 
target novel oncogenic pathways associated with advanced colorectal cancer 
are therefore promising strategies for improving patient outcome.  
Sphingolipids are major components of the membrane bilayer and play 
critical roles in regulating cancer development. The major bioactive 
sphingolipids, ceramide and sphingosine-1-phosphate (S1P), regulate very 
distinct cellular functions. Increased levels of ceramide have been shown to 
promote apoptosis (Kolesnick & Hannun, 1999), while increased levels of S1P 
promote cell proliferation and survival (Cuvillier et al, 1996). The 





‘sphingolipid rheostat’, determined by the relative levels of ceramide to S1P, 
is proposed as a cell fate determinant in cancer (Cuvillier, 2007) and is 
regulated by sphingosine kinases (SphKs) which catalyse the phosphorylation 
of sphingosine to S1P. Whilst there are two known mammalian SphK 
isoforms, SphK1 and SphK2, SphK1 appears to be the predominant oncogenic 
isoform in human cancers (Shida et al, 2008b). SphK1 is up-regulated in 
various forms of cancer including colorectal cancer (Kawamori et al, 2009; 
Kawamori et al, 2006), and is involved in oncogenesis and tumor progression. 
Importantly, SphK1 expression correlates with poor prognosis in breast 
(Ruckhäberle et al, 2008) and gastric (Li et al, 2009) cancer patients, although 
its prognostic value in colorectal cancer has not been previously reported.  
In this project as summarized in Fig.37, we provided evidence for the 
therapeutic significance of SphK1 in colorectal cancer. Analysis of 732 
colorectal adenocarcinoma cases revealed that high SphK1 expression 
correlates with increased tumor sizes, advanced tumor stages and poor 
survival of colorectal cancer patients. Our finding is consistent with previous 
studies, which also showed that SphK1 correlates positively with advanced 
tumor stages and poor survival in astrocytomas (Li et al, 2008), estrogen-
positive breast tumors (Ruckhäberle et al, 2008), pancreatic (Guillermet-
Guibert et al, 2009) and gastric (Li et al, 2009) tumors. Thus, we propose that 
SphK1 may be useful as a prognostic biomarker to identify colorectal cancer 
patients who are at a higher risk of a malignant disease in colorectal cancer.  






Fig.37. Summary of project findings and implications 
CRC, Colorectal Cancer; S1PR1-5, S1P receptors 1-5. 
 
It has been suggested that tumor cells rely on SphK1 activity to sustain 
pro-survival signaling pathways and this is a result of non-oncogene addiction 
(Vadas et al, 2008). This means that the cancer cells are over-reliant on SphK1 
that is over-expressed but not genetically mutated. This hypothesis is 
supported by our results which show that higher SphK1 expression in 
colorectal tumors is significantly associated with more aggressive disease in 
patients (increased tumor sizes, advanced tumor stages and poor survival).  





In vitro, we have shown that SphK1 is highly expressed in several 
colorectal cancer cell lines. Despite having lower SphK1 expression, both 
HCT116 and SW480 cells have the highest increase in SphK1 activity upon 
serum stimulation. We postulate that this may be attributed to the specific 
mutations present in each cell line. In HCT116 cells, the mutation of PI3K 
catalytic subunit results in the hyper-activity of PI3K (Samuels et al, 2004). In 
chapter 5, we demonstrated that PI3K regulates SphK1 activity in HCT116 
cells, thus increased activity of PI3K is likely to result in increased activity of 
SphK1. SW480 cells have the activating epidermal growth factor receptor 
(EGFR) mutation (Table 3), which may confer increased SphK1 activity as 
EGF has been shown to stimulate SphK1 activity in various cancer models 
such as breast cancer (Nava et al, 2002), glioblastoma (Estrada-Bernal et al, 
2011) and gastric cancer (Shida et al, 2008a). Nonetheless, high expression of 
SphK1 in RKO and SW620 cell lines correlates with increased sensitivity to 
SphK1 inhibition by 5c, as shown by PI analysis in Chapter 3, emphasizing 
the role of SphK1 as a pro-survival protein in colorectal cancer.  
SphK1 is a pro-survival protein activated by serum in colorectal cancer 
because blockade of its activity with a novel SphK1-specific inhibitor 
Compound 5c (Wong et al, 2009) induces apoptosis in the colorectal cancer 
cells. The importance of SphK1 in regulating the cell cycle progression is also 
evident in glioblastomas (Van Brocklyn et al, 2005). In addition, we 
deciphered how SphK1 up-regulates colorectal cancer cell survival and 
elucidated novel serum-activated survival signaling involving the PI3K-
SphK1-S1P-Akt and SphK1-S1P-PKCδ-Akt pathways. Therapeutic strategies 





to inhibit SphK1 activity will disrupt these pro-survival mechanisms and drive 
the colorectal cancer cells towards cell death.   
The PI3K pathway is an important pro-survival pathway in colorectal 
cancer. It promotes tumorigenesis, and influences how cancer cells respond to 
anti-cancer treatment such as radiotherapy and chemotherapy (Huang & Hung, 
2009). As illustrated in Figure D in the introduction chapter, PI3K mediates 
most of its pro-survival cellular effects via Akt (Vivanco & Sawyers, 2002). 
PI3K-activated Akt regulates downstream effector molecules such 
MDM2 /p 5 3 , GSK3β, NFκB, BAD, and  FKHR to p romote cell cycle 
progression and inhibit apoptosis. This ties in with the pro-survival roles of 
SphK1 in colorectal cancer, where we found that SphK1 regulates cell cycle 
pregression and the inhibition of SphK1 activity induces apoptosis. 
Akt is the major downstream effector of PI3K. To date, it is not clear if 
there are other proteins mediating the PI3K-induced Akt activity. We have 
contributed to this field of study by demonstrating that SphK1 is novel protein 
that mediate the PI3K-induced Akt activity. PI3K which is activated by the 
stimulation of growth factors, activate downstream SphK1 to activate Akt. 
SphK1 and S1P are mediators for the transactivation of several growth 
factor receptor signaling, including EGFR in breast cancer (Pchejetski et al, 
2008), TGFbeta in oesophageal cancer (Miller et al, 2008) and HER2 in 
gastric cancer (Shida et al, 2005). It is conceivable that through 
transactivation, SphK1 activity in tumors not only amplifies proliferative 
pathways, but also provides alternative survival pathways when growth signals 
are antagonized by drugs. In line with this hypothesis, we found a novel 
feedback loop between SphK1 and PKCδ. In the HCT116 cells, activation of 





SphK1 by serum stimulates PKCδ which activates downstream Akt, and at the 
same time PKCδ feeds back to activate SphK1. This results in an amplification 
of the SphK1-S1P-PKCδ-Akt pathway. We further hypothesize that this novel 
feedback relationship between SphK1 and PKCδ will amplify many other 
pathways that are downstream of SphK1 and PKCδ respectively. This 
amplification of several pro-survival pathways will greatly boost the survival 
of colorectal cancer cells and aid in their resistance to chemotherapeutic 
treatments. 
Future directions would be geared towards dissecting other signaling 
mechanisms of SphK1 in colorectal cancer. Potential upstream players of 
SphK1 such as classical and novel PKCs, PLD, ERK1/2, and downstream 
players such as NFκB and mTOR will be investigated. For example, our group 
has previously shown that SphK regulates downstream NFκB activity in 
primary neutrophils, resulting in pro-inflammatory effects (Issuree et al, 
2009). In this inflammation model, PLD further regulates SphK activity. 
However, the relationship between SphK1, PLD and NFκB is yet unclear in 
colorectal cancer. In addition, mTOR is a regulator of cell growth and it 
appears to be up-regulated in colorectal cancer (Menon & Manning, 2008). 
Since we have shown that high SphK1 expression in colorectal tumors 
correlates to increased tumor size, there may be a potential link between 
SphK1 and mTOR in colorectal cancer that is yet unknown. Overall, 
identifying additional novel mechanisms by which SphK1 promotes cell 
survival will aid in the development of therapeutic strategies to treat colorectal 
cancer. 





Colorectal cancer cells exhibit heightened sensitivity to 5-FU when 
SphK1 activity is inhibited, and the combination of the SphK1 inhibitor 5c 
with 5-FU is more potent than either drug used alone. This suggests that the 
inhibition of SphK1 helps to overcome death resistance to 5-FU in colorectal 
cancer. This hypothesis is consistent with previous studies, showing that 
inhibition of SphK1 helps to overcome death resistance to doxorubicin in 
breast cancer (Nava et al, 2002), imatinib in leukemia (Baran et al, 2007) and 
gemcitabine (Guillermet-Guibert et al, 2009) in pancreatic cancer. Potential 
strategies for the improved treatment of colorectal cancer may be developed 
by exploring combination therapies of SphK1 inhibitors such as 5c with 
current chemotherapeutic agents. In line with our findings, we also propose 
SphK1 to be a chemotherapy sensor in colorectal cancer. Colorectal tumors 
with high SphK1 expression suggest that the patient may need to undergo 
more aggressive anti-cancer regimes to increase their survival chances. 
Future directions would be geared towards establishing inhibitors of 
SphK1 as therapeutic drugs. Toxiocology studies should be performed to look 
at the potential side-effects of SphK1 inhibitors such as 5c and these inhibitors 
should be tested on animal models that mimic colorectal cancer development. 
One example is the azoxymethane-induced colorectal cancer mouse model.  
 In conclusion, we have shown that SphK1 is a pro-survival protein that 
is over-expressed in the colorectal cancer cell lines and patients’ colorectal 
tumor tissues. SphK1 regulates colorectal cancer cell survival via a novel 
SphK1-S1P-PKCδ-Akt pathway. Inhibition of SphK1 activity leads to 
colorectal cancer cell death. Selective inhibitors of SphK1, such as Compound 
5c, enhances the efficacy of other known chemotherapeutic drugs such as 5-





FU to treat colorectal cancer. With an acceptable toxicity, inhibitors of SphK1 
may be explored for their potency as adjunct agents in current 
chemotherapeutic regimes. By targeting SphK1 inhibition as a therapeutic 
strategy, we may effectively eliminate colorectal cancer cell 
survival/proliferation and cancer recurrence, as well as overcome the problem 
of chemotherapeutic drug resistance. This strategy may thus greatly improve 
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Synthesis and Evaluation of Sphingosine Analogues as Inhibitors of 
Sphingosine Kinases 
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Lingkai Wong, Sheryl S.L. Tan, Yulin Lam, Alirio J. Melendez 
 
Sphingolipid-metabolizing enzymes control the critical balance of the cellular 
levels of sphingolipids, including the apoptotic inducing ceramide (Cer) and 
the proliferative inducing sphingosine 1-phosphate (S1P). The production of 
S1P, catalyzed by the action of sphingosine kinases (SPHKs), is known to be 
critical for many cellular processes. However, it is suggested that SPHK, 
and/or its catalytic product S1P, plays critical roles in various diseases 
including autoimmune diseases, cancer, and allergies. However, there is a 
great limitation of specific pharmacological inhibitors for SPHKs. In this 
paper, we describe a novel and stereoselective method of synthesizing SPHKs 
inhibitors. We generated a number of novel compounds and identified a 
number of specific inhibitors of human SPHKs. These compounds 
demonstrated inhibition of SPHKs at micromolar concentrations, making them 
more potent than dimethylsphingosine (DMS), a well-known inhibitor of 
SPHKs. In particular, one of the inhibitors was found to be selective toward a 



























Blockade of SphK1 inhibits colon carcinoma cell proliferation 
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Over the past few years, it has become clear that sphingolipids are sources of 
important signaling molecules in addition to their roles as structural 
components of cell-membranes. In particular sphingosine-1-phosphate (S1P) 
has been implicated in a variety of cellular processes, such as cell 
differentiation, apoptosis, and proliferation. S1P is formed following the 
phosphorylation of sphingosine by sphingosine kinases (SphKs).  Two known 
isoforms of SPHKs in mammalian cells exist (SphK1 and SphK2).  SphK1 has 
been shown to be up-regulated in various cancers, and its expression has been 
correlated to poor prognosis of cancer patients. Here we investigated the role 
of SphK1, expression and inhibition, in several cancers cell lines to better 
understand the potential role of this lipid kinase in tumorigenesis. We show 
that there is a high basal level of SphK1 in most cancer cell-types investigated, 
but it is particularly upregulated in HCT116 colon carcinoma cells. We then 
inhibited SphK activity in these cells, and observed a decline in proliferation. 
One of the best-known inhibitors of SphKs is N,N-dimethylsphingosine 
(DMS). However, DMS is not specific; it inhibits both SphKs as well as other 
enzymes. We have developed novel-specific SphK1 inhibitors; here we 
introduce a selective SphK1 inhibitor (Compound 5c). Our results show that 
Compound 5c inhibits HCT116 cell proliferation as efficiently as DMS, but it 
specifically inhibits SphK1. These results support a key role for SphK1 in 
cancer cell proliferation and suggest that Compound 5c may potentially lead to 
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Background: 
Sphingosine kinases (SphK) have been shown to be involved in cell survival, 
calcium mobilization, cytoskeletal reorganization and chemotaxis. Two known 
isoforms of SphKs in mammalian cells exist (SphK1 and SphK2). 
Interestingly, SphK1 has been shown to be up-regulated in various cancers, 
and its expression has been correlated to poor prognosis of cancer patients. 
Our laboratory has recently shown that proinflammatory molecules, such as 
C5a and TNF-α, signal via SphK1 to induce inflammatory and growth 
responses in human cell lines. The aim of this work is to dissect the role of 
SphK1 in cytokine-mediated colon carcinoma cell growth and migration. 
 
Methods: 
We first investigated the expression of SphK1 in various cancers cell lines and 
showed that there is a high basal level of SphK1 in most cancer cell-types 
investigated, but it is particularly upregulated in HCT116 colon carcinoma 
cells. We then inhibited SphK activity in these cells using N,N-
dimethylsphingosine (DMS), and investigated the effect on cell proliferation, 
migration and invasion. However, DMS is not specific; it inhibits both SphKs 
as well as other enzymes. Therefore, we developed novel-specific SphK1 
inhibitors; here we introduce a selective SphK1 inhibitor (Compound 5c).   
 
Results: 
Our results show that both DMS and Compound 5c inhibit HCT116 colon 
carcinoma cell proliferation, migration and invasion. Importantly, the SphK1-
specific inhibitor Compound 5c inhibits these processes as efficiently as DMS. 
At 5μM, both DMS and Compound 5c were able to inhibit cell proliferation 
by at least 40%. At 10uM, both DMS and Compound 5c were able to reduce 
cell migration and invasion rates to levels comparable to that of basal.  
 
Conclusion: 
Our preliminary results support a key role for SphK1 in cancer cell 
proliferation, migration and invasion. Further mechanistic studies will be 
carried out to dissect the potential role of SphK1 in inflammatory signals (such 
as cytokines) that promote tumorigenesis and metastasis. In this way, SphK1-
specific inhibitors, such as Compound 5c, may potentially lead to the 
generation of a family of novel therapeutics to treat cancer. 
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 Sphingolipids are major components of the membrane bilayer and they 
play critical roles in regulating cancer development. The major bioactive 
sphingolipids, ceramide and sphingosine-1-phosphate (S1P), regulate very 
distinct cellular functions. Increased level of ceramide is important for 
apoptosis while increased level of S1P is important for cell proliferation and 
survival. Therefore, a ‘sphingolipid rheostat’ has been proposed. It refers to 
the dynamic ratio of ceramide to S1P in cells and is important in determining 
cell fate. Any changes in the relative amounts of these 2 antagonistic 
metabolites can potentially alter cell fate. Sphingosine kinase (SphK) is the 
lipid kinase regulating this rheostat and SphK1 is the primary isoform that tilts 
this rheostat towards the production of S1P, thereby promoting cell survival. 
In this project, we showed that SphK1 is up-regulated in both colorectal 
cancer cell lines and human colorectal tumor tissues. Expression of SphK1 
correlates to increased tumor size and poorer survival prognosis in the 
colorectal cancer patients. Using a novel SphK1-specific inhibitor Compound 
5c, we further showed that SphK1 promotes cancer cell proliferation by 
driving the cell cycle progression. Blockade of SphK1 activity using 
Compound 5c induces G1 cell cycle arrest and subsequent apoptosis. 
Therefore, SphK1 is a key player in the development of colorectal cancer and 
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 Sphingolipids are major components of the membrane bilayer and they 
play critical roles in regulating cancer development. The major bioactive 
sphingolipids, ceramide and sphingosine-1-phosphate (S1P), regulate very 
distinct cellular functions. Increased level of ceramide is important for 
apoptosis while increased level of S1P is important for cell proliferation and 
survival. Therefore, a ‘sphingolipid rheostat’ has been proposed. It refers to 
the dynamic ratio of ceramide to S1P in cells and is important in determining 
cell fate. Any changes in the relative amounts of these 2 antagonistic 
metabolites can potentially alter cell fate. Sphingosine kinase (SphK) is the 
lipid kinase regulating this rheostat and SphK1 is the primary isoform that tilts 
this rheostat towards the production of S1P, thereby promoting cell survival. 
In this project, we showed that SphK1 is up-regulated in both colorectal 
cancer cell lines and human colorectal tumor tissues. Expression of SphK1 
correlates to increased tumor size and poorer survival prognosis in the 
colorectal cancer patients. Using a novel SphK1-specific inhibitor Compound 
5c, we further showed that SphK1 promotes cancer cell proliferation by 
driving cell cycle progression. Blockade of SphK1 activity using Compound 
5c induces G1 cell cycle arrest and subsequent apoptosis. 5c further 
potentiates the sensitivity of the anti-cancer drug 5-Fluorouracil (5-FU), 
suggesting that the combination of SphK1 inhibition with current 
chemotherapeutic agents may be developed as potential strategies for the 
treatment of colorectal cancer. Therefore, SphK1 is a key player in the 
development of colorectal cancer and inhibitors of SphK1 such as Compound 
5c are potential therapeutic anti-cancer agents. 
 
